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Ying Liu
The theme of my dissertation is on merging statistical modeling with medical domain knowledge
and machine learning algorithms to assist in making personalized medical decisions. In its simplest
form, making personalized medical decisions for treatment choices and disease diagnosis modality
choices can be transformed into classification or prediction problems in machine learning, where the
optimal decision for an individual is a decision rule that yields the best future clinical outcome or
maximizes diagnosis accuracy. However, challenges emerge when analyzing complex medical data.
On one hand, statistical modeling is needed to deal with inherent practical complications such as
missing data, patients’ loss to follow-up, ethical and resource constraints in randomized controlled
clinical trials. On the other hand, new data types and larger scale of data call for innovations
combining statistical modeling, domain knowledge and information technologies. This dissertation
contains three parts addressing the estimation of optimal personalized rule for choosing treatment,
the estimation of optimal individualized rule for choosing disease diagnosis modality, and methods
for variable selection if there are missing data.
In the first part of this dissertation, we propose a method to find optimal Dynamic treatment
regimens (DTRs) in Sequential Multiple Assignment Randomized Trial (SMART) data. Dynamic
treatment regimens (DTRs) are sequential decision rules tailored at each stage of treatment by po-
tentially time-varying patient features and intermediate outcomes observed in previous stages. The
complexity, patient heterogeneity, and chronicity of many diseases and disorders call for learning
optimal DTRs that best dynamically tailor treatment to each individual’s response over time.
We propose a robust and efficient approach referred to as Augmented Multistage Outcome-
Weighted Learning (AMOL) to identify optimal DTRs from sequential multiple assignment ran-
domized trials. We improve outcome-weighted learning (Zhao et al. 2012) to allow for negative
outcomes; we propose methods to reduce variability of weights to achieve numeric stability and
higher efficiency; and finally, for multiple-stage trials, we introduce robust augmentation to im-
prove efficiency by drawing information from Q-function regression models at each stage. The
proposed AMOL remains valid even if the regression model is misspecified. We formally justify
that proper choice of augmentation guarantees smaller stochastic errors in value function estima-
tion for AMOL; we then establish the convergence rates for AMOL. The comparative advantage
of AMOL over existing methods is demonstrated in extensive simulation studies and applications
to two SMART data sets: a two-stage trial for attention deficit hyperactivity disorder and the
STAR*D trial for major depressive disorder.
The second part of the dissertation introduced a machine learning algorithm to estimate per-
sonalized decision rules for medical diagnosis/screening to maximize a weighted combination of
sensitivity and specificity. Using subject-specific risk factors and feature variables, such rules ad-
minister screening tests with balanced sensitivity and specificity, and thus protect low-risk subjects
from unnecessary pain and stress caused by false positive tests, while achieving high sensitivity
for subjects at high risk. We conducted simulation study mimicking a real breast cancer study
[Pataky et al., 2013], and we found significant improvements on sensitivity and specificity com-
paring our personalized screening strategy (assigning mammography+MRI to high-risk patients
and mammography alone to low-risk subjects based on a composite score of their risk factors) to
one-size-fits-all strategy (assigning mammography+MRI or mammography alone to all subjects).
When applying to a Parkinson’s disease(PD) FDG-PET and fMRI data [Huang et al., 2013], we
showed that the method provided individualized modality selection that can improve AUC, and
it can provide interpretable decision rules for choosing brain imaging modality for early detection
of PD. To the best of our knowledge, this is the first time in the literature to propose automatic
data-driven methods and learning algorithm for personalized diagnosis/screening strategy.
In the last part of the dissertation, we propose a method, Multiple Imputation Random Lasso
(MIRL), to select important variables and to predict the outcome for an epidemiological study of
Eating and Activity in Teens. In this study, 80% of individuals have at least one variable miss-
ing. Therefore, using variable selection methods developed for complete data after listwise deletion
substantially reduces prediction power. Recent work on prediction models in the presence of in-
complete data cannot adequately account for large numbers of variables with arbitrary missing
patterns. We propose MIRL to combine penalized regression techniques with multiple imputation
and stability selection. Extensive simulation studies are conducted to compare MIRL with several
alternatives. MIRL outperforms other methods in high-dimensional scenarios in terms of both re-
duced prediction error and improved variable selection performance, and it has greater advantage
when the correlation among variables is high and missing proportion is high. MIRL is shown to
have improved performance when comparing with other applicable methods when applied to the
study of Eating and Activity in Teens for the boys and girls separately, and to a subgroup of low
social economic status (SES) Asian boys who are at high risk of developing obesity.
Key Words: Personalized medicine; SMARTs; Dynamic treatment regimens; Outcome- weighted
learning; Q-learning; Double robust; Weighted support vector machine; Personalized diagnosis;
Cancer screening; Parkinsons disease; Missing data; Random lasso; Multiple imputation; Variable
Selection; Stability selection; Variable ranking.
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This dissertation includes several projects with the goal to facilitate personalized medical decision
making from disease diagnosis, dynamic treatment regime choice, and prediction prospective. The
dissertation consists of three parts. The first part (Chapter 2) addresses the treatment choice
prospective, where we propose Augmented Multiple-Stage Outcome Weighted learning to estimate
the optimal Dynamic Treatment Regime using data collected from the Sequential Multiple As-
signment Randomized Trials (SMARTs). The second part addresses the diagnostic prospective
(Chapter 3), where we propose a statistical learning approach to choose the best diagnostic modal-
ity according to patients’ heterogeneous characteristics. In the third part (Chapter 5), we propose
Multiple Imputation Random Lasso for prediction and variable selection when missing data is
encountered.
CHAPTER 1. INTRODUCTION 2
1.2 Introduction to a Robust Hybrid Learning Method for Esti-
mating Personalized DTR
Advances in technology are revolutionizing medical research by collecting abundant data for each
individual patient (e.g., clinical assessments, genomic data, electronic health records) for clinical
researchers to meet the promise of individualized treatment and health care. The availability of
these rich data sources provides new opportunities to deeply tailor treatment for each subject in the
presence of the complexity, patient heterogeneity, and chronicity of many diseases and disorders.
Most importantly, dynamic treatment regimes (DTRs, [Lavori and Dawson, 2000]) are a sequence
of interventions in which the treatment decisions are adapted to the time-varying clinical status
of a patient. DTRs are particularly useful in the treatment to complex chronic disorders, such as
substance dependence, attention deficit hyperactivity disorder (ADHD), autism spectrum disorder,
major depressive disorder (MDD), and schizophrenia [Schneider et al., 2003; Rush et al., 2004;
Rush et al., 2006; Oslin, 2005; Jones, 2010]. DTRs are also known as adaptive treatment strategies
[Lavori and Dawson, 2000], multi-stage treatment strategies [Thall et al., 2002; Thall and Wathen,
2005] and treatment policies [Lunceford et al., 2002; Wahed and Tsiatis, 2004; Wahed and Tsiatis,
2006].
Sequential Multiple Assignment Randomized Trials (SMARTs) were proposed [Murphy, 2005]
to best construct DTRs that offer causal interpretation through randomization at each critical
decision point. Methods to identify optimal DTRs from SMARTs data have recently received
attention in the statistical community [Moodie et al., 2007; Lavori and Dawson, 2004; Murphy,
2003; Robins, 2004; Zhang et al., 2012; Zhang et al., 2013; Zhao et al., 2009; Zhao et al., 2012;
Zhao et al., 2014]. (See [Chakraborty and Moodie, 2013] for a detailed review of the literature up to
2013.) Parametric methods based on G-computation [Robins, 2004], Monte Carlo simulation [Lavori
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and Dawson, 2004] and Bayesian approaches [Wathen and Thall, 2008; Arjas and Andreev, 2000;
Arjas and Saarela, 2010] have been proposed. These methods are subject to model misspecification
and are computationally intensive to implement, especially in the presence of high-dimensional
tailoring variables. Instead of modeling the full data generation scheme, semi-parametric methods
have been developed to focus on the contrast of conditional mean outcomes. These include methods
using the “regret function”, which is the expected difference in the outcomes that would have been
observed if patients had taken the optimal treatment in the current stage [Murphy, 2003], and is also
a special case of G-estimation proposed by [Robins, 2004; Moodie et al., 2007]. Other approaches
include regret regression methods [Almirall et al., 2010], marginal structural models and structural
nested mean models [Chakraborty and Moodie, 2013]. [Zhang et al., 2012] and [Zhang et al., 2013]
developed a method based on augmented inverse probability weighting for a single or multiple
stage model. However, all these methods are based on either parametric or semiparametric models
which may lose prediction accuracy in the presence of model misspecification and a large number
of tailoring variables, especially for small or moderate sample sizes in real trials.
Machine learning methods originating from computer science literature have also been recently
introduced to identify optimal treatment regimes using data collected in SMARTs. These methods
are particularly suitable for dealing with a large number of subject-specific variables. For example,
Q-learning first proposed in [Watkins, 1989] was implemented to analyze SMART data by [Murphy
et al., 2006; Zhao et al., 2009]. This is a regression-based method to identify the optimal multi-stage
decision rules, where the optimal treatment at each stage is discovered by a backward induction
to maximize the estimated Q-function (“Q” stands for “quality of action”). Regression based Q-
learning can suffer from incorrect model assumptions, because the optimal treatment is selected by
modeling the Q-function and its contrasts. To remedy these limitations, [Zhao et al., 2012] proposed
outcome weighted learning (OWL), which chooses the treatment rules by directly optimizing the
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expected clinical outcome for single-stage trials. Their simulation studies demonstrated that OWL
outperforms Q-learning, especially in small sample-size settings with a large number of tailoring
variables. More recently, [Zhao et al., 2014] generalized OWL to deal with multiple-stage problems
by a backward iterative method. A direct comparison with [Zhang et al., 2013] was performed in
[Zhao et al., 2014] to demonstrate that a OWL-based methods achieve a greater value function.
In this paper, we propose a hybrid approach to integrate OWL and regression models for Q-
functions, namely, Augmented Multistage Outcome-Weighted Learning (AMOL), to identify the
optimal DTRs from SMARTs. We introduce augmentation of machine learning-based OWL to
improve efficiency by drawing information from regression models at each stage using all subjects
under a proper weighting scheme. More specifically, at each stage, AMOL uses robustly weighted
OWL to estimate the optimal DTRs, where the weights are based on residuals after removing
prognostic effects that are obtained from the observed outcomes and conditional expectations for
subjects who follow the optimal treatment rules in future stages. For those who do not follow
optimal rules in future stages, prediction models for Q-functions are used. Therefore, AMOL
simultaneously takes advantage of the robustness of nonparametric OWL and makes use of model-
based approaches to utilize data from all subjects. Moreover, AMOL yields the correct optimal
DTRs even if the regression models assumed in the augmentation are incorrect, thus maintaining
the robustness of OWL. Theoretically, AMOL is shown to yield the same asymptotic bias as OWL
but possesses smaller stochastic variability due to a better weighting scheme.
1.3 Introduction to Estimating Personalized Optimal Diagnostic
Strategy
Breast cancer screening is one of the most common forms of cancer screening in the United States,
where approximately 39 million screening examinations are performed each year [scr, 2014]. Re-
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cently, there is an increasing demand for personalization of breast cancer screening based on assess-
ment of patient risk, consideration of benefit and harm, and patient preferences [Onega et al., 2014].
Although mammography remains the standard screening modality, new imaging technologies such
as breast magnetic resonance imaging (MRI) may be more sensitive for some women with smaller
lesion size and/or with denser breasts [Pataky et al., 2013].
Similarly, recent research in prostate cancer has led the US Preventive Services Task Force to
recommend prostate-specific antigen (PSA) screening in high risk population instead of the general
population [Moyer, 2012]. To formally study personalized screening strategies, initiatives such as
the Population-based Research Optimizing Screening through Personalized Regimens (PROSPR)
examine how to improve screening process by tailoring based on risk, imaging modalities, and
preferences [National Cancer Institute, 2011].
Besides the potential of personalization in cancer screening, there is also a demand for person-
alized screening in other medical fields such as mental disorders and neurological disorders. For
example, with advances in neurobiology, the current National Institute of Mental Health (NIMH)
Strategic Plan calls for the development of new ways of classifying psychopathology and mental
disorders based on dimensions of observable behavior and biological measures [Fu et al., 2008;
Lilienfeld, 2014]. Brain imaging biomarkers provide an important source of information in addition
to clinical symptoms to assist assessments of of mental disorders, although the science of using
neuroimaging techniques to diagnose psychiatric conditions is in an early stage [Fu et al., 2008;
Ecker et al., 2010]. For neurological disorders, some imaging studies have demonstrated group
differences between patients and matched controls [Huang et al., 2008; Huang et al., 2003]. Given
that patient heterogeneity is commonly observed, it is conceivable that some imaging biomarkers
may be more sensitive in certain subgroups of patients at different stage of disease progression.
However, little work has been done to make personalized selection of imaging modalities, which
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could potentially improve diagnostic accuracy.
Some recent work on personalized medicine have focused on developing machine learning meth-
ods to estimate personalized treatment regimens from data collected in multi-stage clinical trials
[Murphy, 2003; Zhao et al., 2009; Qian and Murphy, 2011]. In contrast, there has been less dis-
cussion on machine learning methods to estimate personalized strategies for medical diagnosis and
screening, despite the clear clinical needs as discussed above. Parametric or semiparametric statis-
tical methods have been developed in the literature to examine heterogeneity in the performance
of medical tests and to combine tests to make diagnosis. For example, there are three approaches
to compare various tests [Pepe, 2003]: empirical methods, distribution modeling methods and
distribution-free parametric methods [Metz et al., 1998; Alonzo and Pepe, 2002]. It is rare that a
single biomarker can achieve adequate diagnostic accuracy, and there is a need to create composite
measures by combining potentially large number of markers. These methods encounter challenges
when the number of biomarkers increases. Some other relevant work aiming at identifying optimal
combination of diagnostic markers include maximum-likelihood estimators based on generalized
linear models or nonparametric models [Pepe et al., 2006; Wang et al., 2011b]. However, their
focus is on improving the overall performance of the combined test applied to the entire sample
under a one-size-fits-all rule that administers the same test to all individuals.
A tempting approach to achieve crude personalization when administering a diagnostic test is to
compare the area under the ROC curve for various testing modalities across subgroups. However,
it is often unknown how to define subgroups, and thus the number of subgroups to be examined
in an exploratory analysis increases exponentially. As a result, such an approach is subject to
penalization by multiple comparisons, and thus cannot accommodate high-dimensional imaging
measures or other biomarkers. Recently, machine learning methods have been developed to estimate
personalized treatment regimens [Zhao et al., 2012]. The advantages of machine learning methods
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include minimal assumptions on the underlying data structure distribution and computational
feasibility to handle high-dimensional feature variables with moderate sample size. Recognizing
these advantages, the goal of this paper is to develop a data-driven machine learning method
to determine the best diagnostic rule to assist personalized recommendation for screening and
diagnostic practices. To the best of our knowledge, this is the first work to propose personalized
diagnosis strategies based on machine learning approaches. The method can easily handle high-
dimensional feature variables and incorporate flexible non-linearity and correlation among variables.
Specifically, we develop a method to estimate optimal personalized screening rules depending on
subject-specific characteristics to maximize their diagnostic performance (weighted combination of
sensitivity and specificity). We show that identifying the optimal diagnostic rule is equivalent to a
weighted classification problem. The estimated diagnostic rule automatically chooses between two
competing modalities for each subject to maximize the performance and is guaranteed to perform
at least as good as assigning the same modality to all subjects (one-size-fits-all rule). Paired and
unpaired designs are considered: in a paired design, both competing modalities are administered
to all subjects; by contrast, each subject receive only one modality in an unpaired design. Theoret-
ical properties are shown including consistency and risk bound of the personalized diagnostic rule.
Simulation studies demonstrate that the proposed method can improve the empirical area under
the receiver operating curve (AUC). Lastly, we give a real data example by analyzing data collected
from a brain imaging study of Parkinson’s disease (PD) using Fludeoxyglucose Positron Emission
Tomography (FDG-PET) or Diffusion Tensor Imaging - Structural Magnetic Resonance Imaging
(DTI-MRI) under paired and unpaired designs. We show that in some real world settings a person-
alized modality assignment rule that improves the empirical AUC compared to a “one-size-fits-all”
strategy and some clinical insights can be drawn from this exploratory analysis.
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1.4 Introduction to Multiple Imputation Random Lasso
In large epidemiological studies, accurately predicting outcomes and selecting variables important
for explaining the outcomes are two main research goals. One commonly encountered complication
in these studies is missing data due to subjects’ loss to follow up or non-responses. It is not
straightforward to handle missing data when performing variable selection since most existing
variable selection approaches require complete data.
Our motivating study is the Eating and Activity in Teens (Project EAT) with a focus of iden-
tifying risk and protective factors for adolescent obesity [Neumark-Sztainer et al., 2012; Larson
et al., 2013]. A primary research goal is to identify the most important household, family, peer,
school, and neighborhood environmental characteristics predicting a teenagers’ weight status in
order to provide recommendations for potential prevention strategies. A strength of Project EAT
is the breadth of potential predictors of weight status collected on 2793 7th and 10th grade teens
from 20 schools in Minneapolis/St. Paul school districts. Weight status was obtained by direct
measurements of height and weight. Predictors were obtained from self-reported questionnaires
from teens themselves as well as from peers (i.e., derived from friendship nominations) and parents
(i.e. from a separate questionnaire sent home to parents). School administrators were surveyed to
obtain variables about food and physical activity policies at schools. Potential predictors describing
the neighborhood built environment (e.g. density of fast food restaurants) were measured using
information from Geographic Information System (GIS) centered at the home residence of each
teen. In total there are 62 predictor variables across the different contexts which are of interest
to examine in terms of their relationship with weight status. This multi-contextual source design
is consistent with recent research paradigms for obesity which view it as impacted by not only
individual behaviors but also social and physical contexts [Frerichs et al., 2012].
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Several risk factors for teenagers’ body mass index (bmi) z-score including higher parental weight
status and peer weight status and lack of neighborhood safety were identified in [Neumark-Sztainer
et al., 2012] and [Larson et al., 2013]. High social economic status has been found consistently to
be a protective factor as well as frequency of family meals. Some factors found to be protective
like having more unhealthy food at home may be more likely to be reactive to weight status rather
than preventing it. For example, when the bmi of a teenager is high, parents may apply higher
restrictions of unhealthy high-calorie food and impose less pressure to eat.
One challenge in analyzing the Project EAT data is that since many measures were collected
with different instruments, 81% of individuals have at least one variable missing data (only 523
of 2793 teenagers had all 62 predictors). We present some of the most frequent missing patterns
in Table 4.1 for 9 variables shown to be important from the analyses by various methods. The
proportion of missing for each data source is different (e.g. 15 − 20% missing from the parent
survey, 40− 44% missing from peer surveys, 2− 10% missing from GIS variables). The missingness
is non-monotone, i.e., does not satisfy monotone missingness: for variables (X1, · · · , Xp), Xj on
an individual is missing implies all subsequent variables Xk is missing for k > j; and there are
a total of 247 distinct complex patterns for all 46 variables with missing entries, which makes it
complicated to model the missingness. Another challenge is that many predictors are moderately
or highly correlated which makes it difficult to separate their effects. The candidate predictors in
Project EAT are naturally classified into family, peer, school and neighborhood measures. The
variables within each class can be highly correlated because students in the same neighborhood
tend to go to the same school, and share the same peer groups.
Our goal is to develop a method to perform variable selection for studies similar to Project EAT
where the number of predictors is large (possibly larger than the sample size), some predictors are
highly correlated, and there is substantial missingness with complicated arbitrary missing data
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patterns.
The most common practice for dealing with missing data is listwise deletion where any obser-
vation missing at least one variable is removed from the analysis and variable selection is applied
to complete data. However, complete case analysis may cause bias when missing completely at
random (MCAR) assumption is not satisfied and will often cause severe loss of information partic-
ularly for high-dimensional data involving non-monotone missing data patterns. There are three
main types of methods to handle missing data. The first group of methods specify the joint dis-
tribution of the variables with and without missing data and compute the observed data marginal
likelihood by integrating over the missing data distribution and performing variable selection by
adapting likelihood-based information criteria developed for complete data [Garcia et al., 2010b;
Garcia et al., 2010a; Ibrahim et al., 2011; Claeskens and Consentino, 2008; Laird and Ware, 1982;
Shen and Chen, 2012].
However, none of these methods are easily applicable to our motivating example, Project EAT,
where the number of variables with missing data is large and missing data patterns are complicated.
It may be computationally intractable to specify a forty-six-dimensional missing data distribution
(both continuous and categorical variables with missing entries) and integrate with respect to this
distribution. In addition, these methods are not applicable when the number of variables p exceeds
the number of observations n, which is the case for the subgroup analysis of Project EAT data.
A second approach to handle missing data in a variable selection setting is through inverse
probability weighting. [Johnson et al., 2008] introduced a general variable selection method based
on penalized weighted estimating equations. However this approach is only applicable to monotone
missing pattern, whereas the project EAT data has a large number of missing data patterns that
are non-monotone and the probability of complete data for some subgroup of subjects are close to
zero. Thus the inverse probability weighting methods are not applicable.
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A third group of methods based on multiple imputation are flexible to deal with non-monotone
and complex missing patterns, thus applicable to our motivating example. A traditional way of
conducting multiple imputation analysis is to conduct linear regression for each imputation and
combine inferences by Rubin’s Rule [Rubin, 1987]. [Wood et al., 2008] recommended applying
classical variable selection methods such as stepwise selection where at each step, the inclusion
and exclusion criterion for a variable were based on overall least square estimators with standard
errors computed from Rubin’s Rule [Rubin, 1987]. [Chen and Wang, 2013] proposed to apply the
group lasso penalty to merged data sets of all imputations, treating the same variable from different
imputations as a group.
The advantages of techniques based on multiple imputation include the convenience of imple-
mentation by using standard software modules and the feasibility for high-dimensional data with
complex missing patterns. There are limitations for classical variable selection method such as step-
wise selection include over-fitting, difficulties to deal with collinearity and relying on p-value based
statistics which do not have the claimed F -distribution [Tibshirani, 1996; Hurvich and Tsai, 1990;
Derksen and Keselman, 1992]. [Chen and Wang, 2013] (CW) is a first attempt to combine multiple
imputation and penalized predicting models. It is feasible for high dimensional cases with complex
missing structure, however, group lasso may be vulnerable to high correlation between variables,
therefore we aim at developing an alternative way to combine the two.
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Chapter 2
Estimating the Optimal DTR for
SMART
2.1 Overview
In this chapter, we propose a method, Augmented Multiple Stage Outcome Weighted Learning
(AMOL), to estimate the best Dynamic Treatment Regime in SMART study. In the Section 2.2,
we review some concepts for DTR, Q-learning, and OWL, and we then introduce AMOL through
robust and efficient augmentation for single-stage and multiple-stage SMART. Section 2.3 presents
theoretical results to justify the theoretical properties of AMOL. In particular, we provide stochastic
error bounds for AMOL and demonstrate its smaller stochastic variability when compared to OWL;
we further derive a fast convergence rate for AMOL. Section 2.4 shows the results of extensive
simulation studies to examine the performance of AMOL compared to Q-learning and OWL. In
Section 2.5, we present data analysis results based on SMART data for an ADHD trial [Pelham Jr
and Fabiano, 2008]. We present another data example for the STAR*D trial [Rush et al., 2004] in
MDD in the Online Supplement. Lastly, we conclude with a few remarks in Section 2.6.
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2.2 Methodologies
2.2.1 Dynamic treatment regimes and outcome weighted learning
We start by introducing notation for a K-stage DTR. For k = 1, 2, . . . ,K, denote Xk as the
observed subject-specific tailoring variables collected just prior to the treatment assignment at
stage k. Denote Ak as the treatment assignment taking values {−1, 1}, and denote Rk as the
clinical outcome (also known as the “reward”) post the kth stage treatment. Larger rewards may
correspond to better functioning or fewer symptoms, depending on the clinical setting. A DTR is a
sequence of decision functions, D = (D1,D2, . . . ,DK), where Dk maps the domain of patient health
history information Hk = (X1, A1, . . . , Ak−1, Xk) to the treatment choices in {−1, 1}. Let πk(a, h)
denote the treatment assignment probability, P (Ak = a|Hk = h). In a SMART, the randomization
probability for each treatment group at each stage is specified by design and thus known to the




To evaluate the causal effect of a DTR, potential outcome framework in causal inference
literature is used. The potential outcome in our context is defined as the outcome of a sub-
ject had he or she followed a particular treatment regimen, possibly different from the observed
regimen. Several assumptions are required to infer causal effects of a DTR using data from a
SMART, including the standard stable unit treatment value assumption and the no unmeasured
confounders assumption [Murphy et al., 2001; Moodie et al., 2007]. Furthermore, we need the
following positivity assumption: for k = 1, ...,K and any ak ∈ {−1, 1} and hk in the support of
Hk, πk(ak, hk) = P (Ak = ak|Hk = hk) ∈ [c, c̃], where 0 < c ≤ c̃ < 1 are two constants. Note that
the no unmeasured confounders assumption is satisfied for SMARTs due to the virtue of sequential
randomization, while the positivity assumption requires that each DTR has a positive chance of
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being observed.
Let P denote the probability measure generated by (X1, A1, R1, . . . , XK , AK , RK). Let PD de-
note the conditional probability measure generated by random variables (X1, A1, R1, . . . , XK , AK , RK)
given that regimen D is used to assign treatment, i.e., Ak = Dk(Hk). Denote ED as the conditional
expectation with respect to the distribution PD. The value function associated with D is defined
as the expected reward given that the treatment assignments follow regimen D [Qian and Murphy,






k=1Rk dPD. Under the positivity assumption, it can












Hence, the goal is to find the optimal treatment rule D∗ that maximizes the value function, that
is, D∗ = argmaxDV(D). Note that if Dk is given as the sign of fk, then the value function is
V(D) = V(f1, ..., fK).
Denote data collected from n i.i.d subjects in a SMART at stage k as (Aik, Hik, Rik) for
i = 1, ..., n, k = 1, ...,K, and note that πk(ak, hk) is known by design. Recently, outcome weighted
learning (Zhao et al., 2012; 2014), abbreviated as OWL, was proposed to estimate the optimal treat-
ment regimes. Specifically, Zhao et al. (2014) proposed a backward induction to implement OWL,
where at stage k, they used only the subjects who followed the estimated optimal treatment regi-









Rik + · · ·+RiK
πik
I(Ai,k+1 = D̂k+1(Hi,k+1), · · · , AiK = D̂K(HiK))∏
j>k πij
+λn‖fk‖2, (2.2)
where πij = πj(Aij , Hij), D̂j(Hij) is the estimated optimal rule at stage j from the backward
CHAPTER 2. ESTIMATING THE OPTIMAL DTR FOR SMART 15
learning algorithm, and ‖f‖ is some norm defined in a function space, usually a reproducing kernel
Hilbert space (RKHS), for f . However, as discussed before, the use of only those subjects who
followed the optimal regimen in future stages may result in information loss especially when K is
not small. Furthermore, [Zhao et al., 2012] suggests to subtract a constant from Rik in order to
ensure a positive weight in the algorithm, where the choice of constant is arbitrary and numerically
influential in the above optimization.
2.2.2 AMOL with K = 1 stage
To describe our proposed method, namely AMOL, we first examine the single-stage randomized
trial setting (K = 1). The basic idea in AMOL to improve OWL by replacing weights R1 in (2.2)
by some surrogate weights, denoted as R̃1, which yields the same asymptotic optimal decision rule
but is less variable. The former guarantees the optimal performance of single-stage AMOL using
the new weighting scheme, while the latter reduces stochastic variability due to finite data.
To achieve both goals, note that if we define R̃1 = R1 − s(H1) for any measurable function
s(H1), depending only on H1 and not A1, then the optimal decision function associated with R̃1 is
E[R̃1|A1 = 1, H1] − E[R̃1|A1 = −1, H1] = E[R1|A1 = 1, H1] − E[R1|A1 = −1, H1], which remains
the same as the one given in OWL. Intuitively, because learning DTR is essential to learn the
qualitative interaction between A1 and H1, then removal of any main effects has no influence.
However, if s(H1) is chosen appropriately, the resultant R̃1 is less variable. Particularly, for AMOL
we propose to obtain s(H1) by fitting a least square lasso regression of R1 on H1. In other words,
the new weights are obtained as the residuals of R1 after removing some linear prediction using
H1.
A computational challenge of using R̃1 as the new weights is that R̃1 can be negative, so the
objective function in a standard SVM is no longer convex. Zhao et al. (2012) solved this issue by
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subtracting an arbitrarily small constant from R̃1 in order to make it positive, which unfortunately
increases the variability of the weights and was demonstrated to be unstable in practice. To solve
this problem, we propose the following procedure. First, note that by simple algebra, the value



















where x− = −min(0, x). Therefore, estimating the optimal decision rule is equivalent to maximizing
the first term on the right-hand side of the above equation, which can be solved empirically by
a weighted SVM, where the weight is |R̃1|/π1(A1, H1), and the class label is A1sign(R̃1). This
guarantees a convex optimization problem that is easy to compute.
To summarize, the proposed AMOL for the K = 1 stage performs the following two steps.
Step 1. Use data (Ri1, Hi1) to obtain an estimator ŝ(H1) = γ̂0 + γ̂
T
1 H1 by fitting a least square
regression or a penalized least square regression if Hi1 is high-dimensional.
Step 2. Obtain R̃i1 = Ri1 − ŝ(Hi1) for each subject, and fit a weighted SVM to estimate the
decision function f1, where the weights are |R̃i1|, and the class labels are Ai1sign(R̃i1). That is, the







were φ(x) = max(0, 1 − x) is the hinge loss. The function class for f1 is an RKHS with either a
linear kernel or a Gaussian kernel. Computationally, this minimization can be carried out using
quadratic programming [Zeileis et al., 2004].
Note that there are two main differences of our proposed method AMOL from OWL: first, we
use a residual variable R̃1 to replace R1; and second, we use |R̃1|/π1(A1, H1) as the new weight
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and A1sign(R̃1) as the new label in a weighted SVM. In Theorems 2.3.1 and 2.3.2 of Sections 2.3,
we formally prove that using this new surrogate weight based on the residuals of R1, the value
loss due to using the estimated treatment rule f̂ has the same deterministic error bound as using
the original R1; however, the error bound due to data randomness is smaller. In this sense, the
value function for AMOL has the same approximation bias as OWL but a smaller stochastic error
asymptotically. Thus, AMOL requires less number of observations than OWL to achieve a similar
performance.
2.2.3 AMOL with K = 2 stages
Next, we consider K = 2. Because DTRs aim to maximize the expected cumulative rewards across
all stages, the optimal treatment decision rule at the current stage must depend on subsequent
decision rules and future clinical outcomes or rewards under those rules. This observation motivates
us to use a backward procedure similar to the backward induction in Q-learning and OWL in [Zhao
et al., 2014].
To estimate the stage 2 optimal treatment rule, AMOL performs the same two steps as in
Section 2.2.2:
Step 2-1. Use data (Ri2, Hi2) to obtain an estimator ŝ2(H2) = γ̂0 + γ̂
T
1 H2 by fitting a least square
regression or a penalized least square regression if Hi2 is high-dimensional.
Step 2-2. Obtain R̃i2 = Ri2 − ŝ(Hi2) for each subject, and fit a weighted SVM to estimate the
decision function f2, where the weights are |R̃i2|/πi2, and the class labels are Ai2sign(R̃i2). That







Now, we consider the estimation of the optimal treatment rule at stage 1. To obtain the optimal
stage 1 rule, a key outcome variable is the so-called Q-function, denoted by Q2, which is the future
CHAPTER 2. ESTIMATING THE OPTIMAL DTR FOR SMART 18
reward increment at future stages if a subject is assigned to the optimal treatment in those stages.
If Q2 was observed for each subject, then the optimal treatment rule at stage 1 would be estimated
using OWL with R1 +Q2 as the weight. For subjects whose treatment assignments at stage 2 are
the same as the optimal treatment rule D∗2, it is clear that Q2 = R2, and thus their weights are
observed; but, for subjects whose treatment assignments at stage 2 are not optimal (i.e., not the
same as D∗2), Q2 is not observed. OWL (Zhao et al., 2014) uses only those subjects whose Q2’s are
observed and multiplied by an additional weight of the inverse probability of treatment assignment.
However, if we treat missing Q2 as a missing data problem, it is well known that the use of only
complete data for estimation may not be the most efficient method; instead, one can use auxiliary
information prior to stage 2, namely H2, to predict Q2 through augmentation for those subjects
with missing Q2 (i.e, for those subjects whose treatment assignments at stage 2 are not the same as
the optimal treatment rule D∗2). Specifically, following the missing data literature [Tsiatis, 2006],










where m22(H2) is some function of H2 serving as the predicted Q2 for subjects with missing Q2
values. Ideally, we want to choose m22(H2) as close as possible to E[Q2|H2]; however, in practice,
because the latter is unknown, and H2 can be high-dimensional, we will estimate m22(H2) as a
linear function of H2 using a weighed least square regression described below. Additionally, because
D∗2 is unknown, we estimate it by the sign of f̂2(H2), which is already obtained in stage 2 of AMOL
(by Steps 2-1 and 2-2).
To estimate the optimal stage 1 treatment rule, AMOL performs the following steps.
Step 1-1. Define D̂2(H2) = sign(f̂2(H2)). Estimate m22(H2) = β0 + βTH2 by a weighted least








and denote the resulting estimator as m̂22.











Step 1-3. Obtain an estimator ŝ1(H1) for s1(H1) = α0 +α




(Ri1 + Q̂i2 − s1(Hi1))2,
and denote R̃i1 = Ri1 + Q̂i2 − s1(Hi1).
Step 1-4. Finally, obtain f̂1 by fitting a weighted SVM with weight |R̃i1|/πi1 and class label
Ai1sign(R̃i1).
Note that the last two steps (Steps 1-3 and 1-4) essentially repeat the same procedure as in the
K = 1 stage, except that the outcome is the augmented outcome variable Ri1 + Q̂i2. In Section 3.2,
we formally show that the above data augmentation method using a surrogate function m22(H2)
for subjects with missing Q2 values will not increase the approximation bias of the value function
estimation based on f̂1; furthermore, we show that compared to OWL, in the estimation of m22(H2)
from a weighted least square in Step 1-1 always leads to a smaller stochastic error bound in the
value function estimation.
2.2.4 AMOL with K > 2 stages
When there are more than two stages, the same backward learning as in K = 2 stages can be ap-
plied, but the data augmentation for those subjects with missing future optimal reward increments
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becomes more complex. For ease of illustration, we consider K = 3 stages, first followed by the
more general case.
To estimate the stage 3 optimal treatment rule, perform the same stage 2 steps for AMOL with
K = 2 (i.e., Steps 2-1 and 2-2 in Section 2.2.3), but with (R2, A2, H2) replaced by (R3, A3, H3). De-
note the resulting estimated decision function at this stage as f̂3(H3), and denote the corresponding
treatment rule as D̂3(H3) = sign(f̂3(H3)).
To estimate the stage 2 optimal treatment rule, perform the same steps as in stage 1 in Section
2.2.3 (Steps 1-1 through 1-4), where (R1, A1, H1) is replaced by (R2, A2, H2), and D̂2 is replaced
by D̂3.
To estimate the optimal stage 1 treatment rule, again, the key outcome variable is R1 + Q2,
where Q2 is the reward increment if a subject takes the optimal treatments in both stages 2 and
3. Clearly, Q2 is only observed as (R2 +R3) for subjects whose treatment assignments agree with
the optimal ones at stages 2 and 3, i.e., A2 = D∗2(H2) and A3 = D∗3(H3). For subjects who do not
follow the optimal treatments either in stage 2 or 3 or both stages, Q2 is missing. However, among
these subjects, some may follow the optimal treatment at stage 2 but not at stage 3; the others do
not follow the optimal treatment at stage 2. This results in a monotone missingness pattern, and
for subjects in the former group, the observed data prior to stage 3 partially contributes to Q2.
Therefore, to make use of the partial observed data and account for different missing patterns in
order to improve the augmentation, following [Tsiatis, 2006], we propose the following augmented
variable for Q2:


















where m23(H3) is a function to approximate the optimal reward increment for subjects who receive
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the optimal treatment at stage 2 and non-optimal treatments at stage 3, and m22(H2) is an ap-
proximation to the optimal reward increment for subjects who receive non-optimal treatments at
stage 2.
Therefore, according to Theorem 2.3.3, to be given in Section 3, to estimate the optimal stage
1 rule, AMOL performs the following steps.















Denote those estimators as m̂23(H3) and m̂22(H2), respectively.
Step 1-2. Calculate
Q̂i2 =

















Step 1-3. Obtain an estimator ŝ1(H1) for s1(H1) = α0 + α
TH1 by the least square
n∑
i=1
(Ri1 + Q̂i2 − s1(Hi1))2,
and denote R̃i1 = Ri1 + Q̂i2 − s1(Hi1).
Step 1-4. Finally, we obtain f̂1 by fitting a weighted SVM with weight |R̃i1| and class label
Ai1sign(R̃i1).
For general K > 2 stages, we implement the same backward AMOL. Specifically, to estimate
the optimal (k − 1)th-stage treatment rule, for j ≥ k, let Mi,k−1 = 1, and let Mij = I(Aik =
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D∗k(Hik), ..., Aij = D∗j (Hij)) denote whether subject i follows the optimal treatment regimens from
stage k to j. Let Cij = Mi,j−1{1 − I(Aij = D∗j (Hij))} indicate that subject i follows the optimal
treatment up to stage j − 1 but does not do so in stage j. Corresponding to the optimal rule







iK includes all of the potential interim outcomes and health information between stage
k and the last stage K if the optimal treatment rule (D∗k, ...,D∗K) was implemented from k to K.
However, due to randomization of the treatment assignments after stage k, no all the subjects




iK ) is not fully




iK ) may be missing. Instead, the observed data follow
a monotone missing pattern: for subject i with Cij = 1, we only observe Hik and a subset of H
(D∗)
iK
which treatments from stage k to (j − 1) are optimal and treatment j is not; and only subjects




iK ). From the theory of Robins (1994), also
seen in Tsiatis (2006) and Zhang et al. (2013), the optimal estimation of Qik under the monotone
missingness and coarsening at random assumption is to use the following augmentation:
MiK(Rik + ...+RiK)






P (Cij = 1|Mi,j−1 = 1, Hij)Mi,j−1 − Cij
P (Mij = 1|H(D∗)ij )
m∗kj(Hij),
where m∗kj(Hij) = E(Qik|Hij ,Mi,j−1 = 1) is the optimal augmentation term. From the sequential
randomization, we know





P (Cij = 1|Mi,j−1 = 1, Hij) = 1− πj(D∗j (Hij), Hij).
Note that with k = 2, the above general expression for Qik reduces to (2.3) for estimating the
optimal stage 1 rule in the case of K = 3.
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To implement AMOL, at stage k − 1, assume that we have already obtained the optimal rules
after this stage, denoted by D̂k, ..., D̂K . Define
M̂ij = I(Aik = D̂k(Hik), ..., Aij = D̂j(Hij)),
and define Ĉij similarly. We estimate P (Mij = 1|H(D
∗)
ij ) by P̂ (Mij = 1|Hij) =
∏j
s=k πs(D̂s(His), His)
and estimate P (Cij = 1|Mi,j−1 = 1, Hij) by P̂ (Cij = 1|Mi,j−1 = 1, Hij) = 1 − πj(D̂j(Hij), Hij).
Then, the augmented variable for Qik is calculated as
Q̂ik =
M̂iK(Rik + ...+RiK)




P̂ (Cij = 1|Mi,j−1 = 1, Hij)M̂i,j−1 − Ĉij
P̂ (Mij = 1|Hij)
m̂kj(Hij), (2.4)













Once Q̂ik is obtained, the algorithm to estimate AMOL proceeds exactly the same as in Steps 1-3
and 1-4 of this section.
As shown in Theorem 2.3.3 of Section 3, the approximation error bound for the value loss of
AMOL using the augmented weights remains the same as OWL; however, the stochastic error bound
of AMOL is smaller. Hence, the value estimation from AMOL is more efficient than OWL using the
same approximation bias. As a note, for randomized trials where the randomization probabilities
πj(Aj , Hj) are known by design, the choice of mkj(Hj) can be arbitrary, and can include interactions
among Hij ’s. From missing data literature, the optimal choice of mkj(Hj) is E[Qk|Hj ,Mj−1 = 1].
Note that the latter may not be well estimated when Hj is not low-dimensional. However, our
theoretical result shows that the use of a linear function of mkj(Hj) is sufficient to yield AMOL
with smaller stochastic variability than OWL.
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2.3 Theoretical Results
In this section, we provide theoretical justification for the proposed method. Specifically, we show
that the stochastic bound for the value function using the proposed estimator is smaller than the
one for OWL. Furthermore, we provide convergence rates for AMOL, in terms of noise conditions
near the optimal decision boundary.
2.3.1 A general asymptotic risk bound for weighted support vector machines
When K = 1, both AMOL and OWL are some form of weighted learning methods, so we consider a
generic weighted learning framework, where the weighting variable is a general non-negative random
variable denoted by R, the treatment variable is denoted by A, and the covariate is a d-dimensional
vector denoted by H. To emphasize the role of (R,A,H), we use V(f ;R,A,H) to denote the value
function associated with f , that is,
V(f ;R,A,H) = E [RI(Af(X) > 0)/π(A,H)] ,
where π(a, h) = P (A = a|H) which is assumed to be known and within [c, c̃] for some positive
constants c and c̃. The optimal rule is then f∗(H) = sign(E[R|A = 1, H]−E[R|A = −1, H]). With
n i.i.d data (Ri, Ai, Hi), an outcome weighted learning method estimates f
∗ via a weighted support






φ(Aif(Hi)) + λn‖f‖2, (2.5)
where φ(x) = (1 − x)+, and ‖f‖ is a norm from a Gaussian RKHS Hσn with bandwidth equal to
σn. Let f̃ be the minimizer. Then, the following theorem provides a general risk bound for the
value loss due to the use of the estimated decision rule f̃ .






and m2 = E[R














+Rφ(g∗;R,A,H)−Rφ(f∗;R,A,H) + cdλnσd/2n .










for any 0 < p < 2, where k(p, d) is a constant that depends only on p and d.
Proof. To avoid confusion, we abbreviate (R,A,H) in the definition of V and Rφ. Using Theorem
3.2 in Zhao et al. (2012), we have
V(f∗)− V(f̃) ≤ Rφ(f̃)−Rφ(f∗).
Let f∗λn be the function that minimizes λn‖f‖2 +Rφ(Af) in Hσn . Then it is clear that when n is
large enough,
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for any f ∈ Hσn , along the same lines as in Steinwart and Scovel (2007) and Zhao et al. (2012),
we obtain































where Pn denotes the empirical measure, and P is the true probability measure. Finally, note that
g∗ takes a value in [−1, 1] and lies in Hσn with its norm bounded by cdσd/2n (c.f., Theorem 2.7,







+Rφ(g∗)−Rφ(f∗) + cdλnσd/2n .
We thus obtain the first part of Theorem 2.3.1.
To prove the second half of Theorem 2.3.1, we compute the bracket covering number of some
finite balls in Hσn . First, from Theorem 2.3.1 in Steinwart and Scovel (2007), the entropy number
for the unit ball in Hσn , denoted by On, satisfies
logN (ε,On, ‖ · ‖∞) ≤ c1(p, d)σ−(1−p/4)dn ε−p
for a constant c1(p, d), so it yields
logN[](ε,On, ‖ · ‖L2(P )) ≤ c1(p, d)σ−(1−p/4)dn ε−p.




f : f ∈ Hσn , ‖f‖2 ≤ 2m2/(cλn)
}
, ‖ · ‖L2(P )) ≤ c1(p, d)σ−(1−p/4)dn ε−p(2m2/(cλn))p/2.
Note that Rφ(Af)/π(A,X) is Lipschitz continuous with respect to f in the sense of
|Rφ(Af1)/π(A,X)−Rφ(Af2)/π(A,X)| ≤ c−1R|f1(X)− f2(X)|.
Therefore, it gives




Rφ(Af)/π(A,X) : f ∈ Hσn , ‖f‖2 ≤ 2m2/(cλn)
}
, ‖ · ‖L2(P ))
≤ c2(p, d, c)σ−(1−p/4)dn ε−p(m2)3p/2/λp/2n .
Finally, R/π(A,X) is the envelop function for the above set of functions with its L2(P ) norm



















, ‖ · ‖L2(P ))dε
≤ k(p, d)n−1/2σ−(1/2−p/8)dn m1+p/42 /λp/4n ,
where c2 is a universal constant and k(p, d) is a constant depending on p and d.
The function g∗(x) was used in the proof of Theorem 2.7 in Steinwart and Scovel (2007) and is
considered to be the best approximation of f∗ in Hσn . Theorem 2.3.1 shows that the asymptotic
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risk bound for the value loss due to the estimated rule f̃ consists of both stochastic error and
approximation error. The former arises from estimation using finite data and depends on both
sample size and the complexity of the function class for f ; the latter is due to the approximation
of the Bayesian rule in Hσn .
Remark 1. In Theorem 2.3.1, we notice that the stochastic error bound is proportional to m
1+p/4
2 .
In fact, using the symmetrization and the result for Rademacher sequences in Theorem 3.14 of
[Koltchinskii, 2011], a multiplier of m
1+p/4
2 is also a lower bound for the stochastic error term in
the right-hand side of the inequality in Theorem 2.3.1. In other words, the stochastic error of the
value loss due to the use of estimated f̃ is on the scale of a positive power of m2. Therefore, when
comparing two different weighted learning methods, we expect that the weighting scheme with a
smaller second moment should provide a smaller stochastic error in the estimation of the value
function.
2.3.2 Improved risk bound of AMOL for K = 1 stage
We use the risk bound in Theorem 2.3.1 to compare OWL and the proposed AMOL for the K = 1
stage. For OWL, R = R1, A = A1, and H = H1; in contrast for AMOL, because the surrogate loss
function is |R1 − s(H1)|φ(A1sign(R1 − s(H1))f(H1))/π(A1, H1), if we denote |R1 − s(H1)| by Rs1,
A1sign(R1 − s(H1)) by Ã1, and πs(a, h) = P (As1 = a|H1 = h), then the corresponding (R,A,H)
for AMOL is R = Rs1π
s(As1, H1)/π(A1, H1), also denoted by R̃1, A = Ã1, and H = H1. Then, the
following theorem compares the risk bound in Theorem 2.3.1 of OWL and AMOL.
Theorem 2.3.2. For any f ∈ L2(P ),
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Furthermore, if f ∈ [−1, 1],
Rφ(f ;R1, A1, H1) = Rφ(f ; R̃1, Ã1, H1),










In general, the above results hold if Rs1 = |R∗1−s(H1)|, where R∗1 satisfies E[R∗1|A1, H1] = E[R1|A1, H1]
and E[(R∗1)
2] ≤ E[R21], and s(H1) minimizes E[(R∗1−s(H1))2] among a class of functions containing
0.
Proof. The first equality is obvious since
Rs1I(Ã1f(H1) > 0) = (R1 − s(H1))+I(A1f(H1) > 0) + (R1 − s(H1))−I(A1f(H1) < 0)
= (R1 − s(H1))I(A1f(H1) > 0)− (R1 − s(H1))−.
To prove the second equation in the theorem, we define
d(H1) = E[R1|A1 = 1, H1] + E[R1|A1 = −1, H1], P̃ (A1 = a|H1) = d(H1)−1E[R1|A1 = a,H1].
Note that













where F (·) is the distribution of H1. Thus,
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where Ẽ[·|H1] is the conditional expectation under the distribution given by P̃ (a|H1). Using the
well-know Zhang’s inequality (c.f., Theorem 2.31, Steinwart and Christmann, 2008), we obtain








|f(H1)− f∗(H1)||E[R1|A1 = 1, H1]− E[R1|A1 = −1, H1]|dF (H1).
On the other hand, we apply the same argument to Rφ(f ; R̃1, Ã1, H1). Since
E
[
Rs1P (Ã1 = 1|H1)
π(A1, H1)
∣∣∣Ã1 = 1, H1] = E[Rs1I(R̃− s(H1) > 0)|A = 1, H1]





∣∣∣Ã1 = 1, H1]− E [R̃1∣∣∣Ã1 = −1, H1]
= E[(R1 − s(H))|A1 = 1, H1]− E[(R1 − s(H1))|A1 = −1, H1]
= E[R1|A1 = 1, H1]− E[R1|A1 = −1, H1].
Thus,




|f(H1)− f∗(H1)||E[R1|A1 = 1, H1]− E[R1|A1 = −1, H1]|dF (H1).
We then obtain the second equation in Theorem 2.3.2. Finally, the third inequality holds since
E[R̃21] ≤ E[|R1 − s(H1)|2] ≤ E[R21].
The last step is true since s(H1) minimizes E[(R1 − s(H1)2)] in a class containing 0. In general, if
Rs1 = |R∗1 − s(H1)|, the above proof still holds.
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Remark 2. The first result in Theorem 2.3.2 implies that the true value loss is the same for OWL
and AMOL. Because g∗ and f∗ are bounded by 1, the second equality in Theorem 2.3.2 implies
Rφ(g∗;R1, A1, H1)−Rφ(f∗;R1, A1, H1) = Rφ(g∗; R̃1, Ã1, H1)−Rφ(f∗; R̃1, Ã1, H1).
In other words, the approximation error bounds are the same for OWL and AMOL. The third
inequality in Theorem 2.3.2 indicates that the stochastic error bound in AMOL is smaller than the
one in OWL, because the weights in AMOL are less variable, and by Remark 1 after Theorem
2.3.1, this leads to a smaller stochastic error.
Remark 3. The general result shows that to obtain a smaller risk bound, we need to identify a
surrogate outcome for R1, which has the same conditional means but smaller variability. In the
subsequent presentation, we will refer to a surrogate outcome R∗1 as “unbiased” (as compared to
OWL) if E[R∗1|A1, H1] = E[R1|A1, H1], because it guarantees the same approximation error bound
in Theorem 2.3.1; we will refer to a surrogate outcome R∗1 as “efficient” (as compared to R1 in OWL)
if E[(R∗1)
2] ≤ E[R21], because it leads to a smaller stochastic error asymptotically. Therefore, the
main idea of AMOL is to identify an unbiased and efficient surrogate outcome R∗1.
Remark 4. The result in Theorem 2.3.2 also shows that using a residual variable R∗1 − s(H1) as a
surrogate outcome for R1 does not increase the approximation error; however, if s(H1) is chosen to
reduce the overall variability of this outcome, then the stochastic error can be reduced. Particularly,
in the AMOL implementation, s(H1) is obtained as the minimizer of E[(R
∗
1 − s(H1))2] in a linear
function class of H1; thus, the last result in Theorem 2.3.2 shows that AMOL is more efficient than
OWL.
2.3.3 Improved risk bound for AMOL for K > 1 stage
We study the asymptotic risk bound for AMOL for the K > 1 stage. The key constant in the
asymptotic bound in Theorem 2.3.1 is the second moment of the surrogate outcome. In this
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section, we will examine such constants of AMOL for K > 1 stage and demonstrate that these
constants are smaller than the constants for OWL. For a general K > 1 stage study, as shown in










P (Cj = 1|Mj−1 = 1, Hj)Mj−1 − Cj




where Cj = Mj−1 − Mj , and mkj(Hj) is a function to approximate the conditional mean of
E[Qk|Hj ,Mj−1 = 1]. Clearly, OWL corresponds to a special case of using R̃k−1(mkk, ...,mkK)
with mkj = Rk−1 for all j ≥ k. The following theorem states that if mkj is chosen properly to
minimize certain weighted least square criteria, then AMOL is more efficient than OWL.
Theorem 2.3.3. For any mkj(Hj) ∈ L2(P ), k ≤ j ≤ K,
E[R∗k−1(mkk, ...,mkK)|Ak−1, Hk−1] = E[Rk−1 +Qk|Ak−1, Hk−1].
Furthermore, if mkj(Hj) is a function that minimizes the weighted least square
E
{
(1− πj(D∗j (Hj), Hj))∏
k≤l≤j πl(D∗l (Hl), Hl)
(mkj(Hj)− (Rk + ...+RK))2
}
among a class of functions containing mk0 = Rk−1, for example, linear functions of Hj. Then
E[R∗k−1(mkk, ...,mkK)
2] ≤ E[R∗k−1(mk0, ...,mk0)2].
Proof. Since Qk = Rk + ....+RK for MK = 1 and
E[
Cj − P (Cj = 1|Mj−1 = 1, Hj)Mj−1
P (Mj = 1|Hj)
|Hj ] = 0,
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(1− πj(D∗j (Hj), Hj))∏








(1− πj(D∗j (Hj), Hj))∏













(1− πj(D∗j (Hj), Hj))∏
k≤l≤j πl(D∗l (Hl), Hl)
(
[mkj(Hj)− (Rk + ...+RK)]2
− [mk0(Hj)− (Rk + ...+RK)]2
)}
.
Since mkj(Hj) minimizes the weighted least square
E
{
(1− πj(D∗j (Hj), Hj))∏
k≤l≤j πl(D∗l (Hl), Hl)
(mkj(Hj)− (Rk + ...+RK))2
}
among a class of functions including mk0(Hj) = Rk−1, we thus conclude the second half of Theorem
2.3.3.
According to Remark 4, Theorem 2.3.3 implies that no matter what mkj(Hj) is, AMOL is
always unbiased. Moreover, if we choose mkj(Hj) to minimize the above weighted least square
among a class of linear functions of Hj , which includes mk0(Hj), then AMOL is more efficient than
OWL. As an application of Theorem 2.3.3 to the special case when K = 2, at stage k = 2 of AMOL,
the surrogate outcome is chosen to be R∗2 = R2; while at stage k = 1, the surrogate outcome is










where m22(H2) is a linear function of H2 that minimizes
E[(R2 −m22(H2))2ω(H2)], where ω(H2) = (1− π2(D∗2(H2), H2))/π2(D∗2(H2), H2).
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Then, AMOL is unbiased and more efficient than OWL. We also note that when π2(A2, H2) = 1/2,
m22(H2) can be obtained as the standard least square estimator for R2 on H2.
2.3.4 Fast convergence rate of AMOL
In this section, we follow Steinwart and Scovel (2007) to obtain a fast convergence rate with
additional noise conditions near the Bayesian boundaries. We first establish the theoretical results
for a generic single-stage AMOL, where the outcome variable can be allowed to be derived variable
using data. Using the same generic notation as in Section 3.1, our first theorem provides the risk
bound for V(f̂), where f̂ minimizes (2.5) with R̃ = ĝ(R,A,H) for a data-dependent function ĝ(·)
and s(H) = ŝ(H) for some estimated function ŝ(·). We assume that
η∗(x) =
E[R|A = 1, X = x]− E[R|A = −1, X = x]
E[R|A = 1, X = x] + E[R|A = −1, X = x] +
1
2
satisfies the following geometric noise exponent condition (c.f., Steinwart and Scovel, 2007):
Definition 2.3.4. (Geometric noise exponent condition (q, p)). For a given function η(x), we
define
O+ = {x ∈ Supp(X) : 2η(x)− 1 > 0} , O− = {x ∈ Supp(X) : 2η(x)− 1 < 0} .
Let ∆(x) = d(x,O+) if x ∈ O−, ∆(x) = d(x,O−) if x ∈ O+, where d(x,O) is the distance of x
from a set O. Then η(x) ∈ (0, 1) is assumed to satisfy condition GNE(q) if there exists a constant









where p is the dimension of X.
As explained in Zhao et al. (2012), this geometric noise exponent condition describes the distri-
bution behavior in a neighborhood of the optimal treatment rule. In the situation that the optimal
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treatment assignment is distinct, i.e., |2η∗(x) − 1| > δ for some positive constant δ, q can be any
large number.
Theorem 2.3.5. Suppose that the RKHS is the Gaussian kernel space with bandwidth σn. Under
the GNE(q) condition, assume that σn = λ
−1/(q+1)p
n , λn → 0, and nλn → ∞. Additionally, we




E[|ĝ(R,A,H)− g∗(R,A,H)|+ |ŝ(H)− s∗(H)|] ≤ c′τ/nβ
}
> 1− e−τ ,
and P
{




> 1− e−τ for some constants c′ and β > 0. Then for any δ > 0,
0 < v ≤ 2, there exists a constant c such that for all τ ≥ 1,
P
{
V(f̂) ≥ V(f∗)− εn(τ)
}


























This theorem implies that V(f̂)→ V(f∗) in probability and, moreover,



















The proof of Theorem 2.3.5 follows from a similar argument to [Zhao et al., 2012], so we do not
provide details here. In the above convergence rate for V(f̂) − V(f), the rate n−β is due to the
stochastic approximation of ĝ and ŝ, the rate λ
q/(q+1)
n arises from the approximation of the RKHS,
and the remaining two terms reflect the stochastic error of the empirical value function evaluated
at f̂ . The constant in this convergence rate, which is derived from the same constant CL in [Zhao
et al., 2012], can be shown to be proportional to m1+p
′
2 , where m2 is the second moment of R̃,
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and p′ = max(0, (2 − 3p)/(2 + p)). The latter is similar to the one Theorem 2.3.1 with a slightly
different power due to additional noise conditions. Consequently, if E[R̃2|H] ≤ E[R2|H], then the
risk bound for weight of R̃ is less than using original R, implying that a less variable weight R̃
should lead to a tighter risk bound for V(f̂).
Next, we establish some theoretical properties for the AMOL with K > 1 stages. Specifically,
our last theorem gives the value loss due to the estimated DTRs in the AMOL. Recall that a
treatment decision rule for the multi-stage DTR is determined by a sequence of functions f =
(f1, f2, ..., fK) which maps from (H1, ...,HK) to {−1, 1}K . The value function associated with this
treatment decision rule is defined as










Further, define the value function at the kth-stage as










Then, the following theorem gives the main result regarding Vk(f∗k , ..., f∗K) − Vk(f̂k, ..., f̂K) for
k = 1, ...,K, where (f∗1 , ..., f
∗
K) are the theoretical optimal treatment rules as given in [Zhao et al.,
2012].
Theorem 2.3.6. Let η∗k be defined the same way as η
∗ with the following substitution: A = Ak, X =
Hk and substitute R with the summation of Rk and the optimal rewards for all future stages. Assume
(C.1) η∗k satisfies the GNE condition with q = qk and p = pk.







E[|m̂kj(Hj)−m∗kj(Hj)|+ |ŝk(Hk)− s∗k(Hk)|] ≤ c′τ/nβk
 > 1− e−τ
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and P
{∑




> 1− e−τ for some constants c′ and βk > 0.
(C.3) The RKHS is the Gaussian kernel space with bandwidth σnk = λ
−1/(qk+1)pk
nk , and λnk satisfies
nλnk →∞.
Then it holds that for any δk > 0, 0 < vk ≤ 2, there exists a constant c such that for all τ ≥ 1,
P






































for some function q(p, d, c′) and R̃j =
Rj +Qj+1 − sj(Hj), where Qj+1 is is defined in Section 2.4 with mkj = m∗kj.
Proof. Proof of Theorem 2.3.6. We define a conditional value function at stage k as









Clearly, Vk(fk, ..., fK) = E [I(Ak = sign(fk(Hk)))Uk(Hk+1; fk+1, ..., fK)/πk(Ak, Hk)] . In AMOL for
the K-stage trial, f̂k minimizes









Rik + Q̂i,k+1 − ŝk(Hik)
]
,
where Q̂i,k+1(Hk+1) is the estimator given in Section 2.4.
At the final stage, f̂K is essentially the estimated rule from a single-stage AMOL, so from
Theorem 2.3.5, we have
P (VK(f∗K)− VK(f̂K) ≤ εK(τ)) ≥ 1− e−τ , (2.6)
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based on Theorem 2.3.5 and the exponent
qK in the GNE condition for the K-th stage. Furthermore, we obtain ‖f̂K‖ ≤ c/
√
λnK for some
constant with at least probability 1− e−τ/4.
For k = K − 1, we note that
VK−1(f∗K−1, f∗K)− VK−1(f̂K−1, f̂K)
≤ VK−1(f∗K−1, f∗K)− VK−1(f∗K−1, f̂K) + VK−1(f∗K−1, f̂K)− VK−1(f̂K−1, f̂K).
On the other hand, since
UK−1(HK ; f
∗



































where c0 is the lower bound for πk(ak, hk) for k = 1, ...,K. Hence,





+ VK−1(f∗K−1, f̂K)− VK−1(f̂K−1, f̂K). (2.7)
We define
f̃K−1 = argmaxfVK−1(f, f̂K).
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Then 2.7 gives







VK−1(f̃K−1, f̂K)− VK−1(f̂K−1, f̂K)
}
. (2.8)
Note that the second term on the right-hand side of 2.8 is essentially the value loss due to using
f̂K−1 if we restrict to the population where AK = sign(f̂K). Thus, if we let





−I(AK = sign(f(HK)))− πK(AK , HK)
πK(AK , HK)
mK−1,K(HK) +RK−1 − s(HK−1)
}
,



















−E[ω(f̂K ,m∗KK , s∗K−1)I(AK−1f̂K−1(HK−1) > 0)]
= E[|ω(f̂K ,m∗KK , s∗K−1)|I(AK−1sign(ω(f̂K ,m∗KK , s∗K−1))f̂K−1(HK−1) ≤ 0)]
−E[|ω(f̂K ,m∗KK , s∗K−1)|I(AK−1sign(ω(f̂K ,m∗KK , s∗K−1))f̃K−1(HK−1) ≤ 0)].
Moreover, using the excess risk result in Theorem 3.2 of Zhao et al. (2012) (also see Barlett et al.
2006), we obtain
VK−1(f̃K−1, f̂K)− VK−1(f̂K−1, f̂K) ≤ Rφ(f̂K−1; f̂K ,m∗KK , s∗K−1)−Rφ(f̃K−1; f̂K ,m∗KK , s∗K−1),
(2.9)
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where




E[|m̂KK(HK)−m∗KK(HK)|+ |ŝK−1(HK−1)− s∗(HK−1)|] ≤ c1τ/nβK−1
}
.
According to (C.2), P (A) > 1− e−τ/2. Furthermore, on this set, it is clear that
sup
f
|Rφ(f ; f̂K ,m∗KK , s∗K−1)−Rφ(f ; f̂K , m̂KK , ŝK−1)|
≤ c2E[|m̂KK(HK)−m∗KK(HK)|+ |ŝK−1(HK−1)− s∗K−1(HK−1)|]
+c2E[|ω(f̂K ,m∗KK , s∗K−1)||sign(ω(f̂K , m̂KK , ŝK−1))− sign(ω(f̂K ,m∗KK , s∗K−1))|]
for some constant c2 depending on c
′ and π0. If
sign(ω(f̂K , m̂KK , ŝK−1))− sign(ω(f̂K ,m∗KK , s∗K−1) 6= 0,
then









|Rφ(f ; f̂K ,m∗KK , s∗K−1)−Rφ(f ; f̂K , m̂KK , ŝK−1)| ≤ c3τ/nβK−1
for some constant c3.
Therefore, combining the results from 2.6 —2.9, we obtain that by re-defining a constant c in
εK(τ), with at least 1− 3e−τ/2 probability, we have
VK−1(f̂K−1, f̂K) ≥ VK−1(f∗K−1, f∗K)− c−10 εK(τ)− c
τ
nβK−1
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−
{
Rφ(f̂K−1; f̂K , m̂KK , ŝK−1)−Rφ(f̃K−1; f̂K , m̂KK , ŝK−1)
}
. (2.10)
Hence, to prove the theorem for K − 1, it suffices to derive a stochastic bound for the last term on
the right-hand side of 2.10.
Note that this term is the excess risk if we treat Rφ(f ; f̂K , m̂KK , ŝK−1) as the loss function.
Clearly, f̃K−1 is the minimizer and based on the definition of f̂K−1, f̂K−1 minimizes its correspond-
ing empirical version with regularization:










−I(AiK = sign(f̂K(HiK)))− πK(AiK , HiK)
πK(AiK , HiK)
m̂KK(HiK) +Ri,K−1 − ŝK−1(Hi,K−1)
}
.
The derivation of the stochastic bound follows the same arguments used in the proof of Theorem
3.4 in Zhao et al. (2012). The only difference is that the loss function corresponding to Rφ, i.e.,
l(f) ≡ |ω(f̂K , m̂KK , ŝK−1)|(1−AK−1sign(ω(f̂K , m̂KK , ŝK−1))f(HK−1))+,
depends on f̂K and m̂KK as well as ŝK−1. Since the latter are all bounded by cτ/
√
λn,K with prob-
ability at least 1−e−τ/8 for a large c, the ε-entropy number for l(f) is bounded by cε−vσ(1−v/2)(1+δ)n
for any v ∈ (0, 2) and δ > 0. Therefore, from Theorem 5.6 in Steinwart and Scovel (2007) and
using conditions (C.1) and (C.3), we conclude that with at least probability 1− e−τ/2,




















where c = k(p, d, c′)
{
E[(RK−1 +QK − s∗K−1(HK−1))2]
}max(1/2,(2−p)/(2+p))
.
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Finally, combining 2.10 and 2.11 yields
P
{
VK−1(f∗K−1, f∗K)− VK−1(f̂K−1, f̂K) ≤ c−10 εn,K(τ) + εn,K−1(τ)
}
≥ 1− 2eτ .
By repeating the above proofs for stage K − 2 through stage 1, we obtain the result in Theorem
2.3.6.
The above condition (C.1) is the standard condition in support vector machine theory, and
this condition describes the data distribution near the optimal separation boundary at each stage.
Condition (C.2) is the assumed condition for the prediction model to estimate gk and sk. This
condition holds naturally for βk < 1/2 if mkj and sk are from a parametric working model. This
theorem implies that Vk(f̂k, ..., f̂K) → Vk(f∗k , ..., f∗K) in probability. Furthermore, the convergence
rate of this approximation depends on the separability of the optimal treatment regimes, which is
reflected by qk in the geometric noise exponent condition, and the approximation of the weights in
terms of βk from all stages from stage k. As a final note, the convergence rate is the same as what
is given in Zhao et al. (2014); however, the most important reduction in the proposed method
is that we can shrink the constant significantly if a proper augmentation is used in AMOL. In
the subsequent numerical studies, this will be demonstrated to have a big improvement over their
approach with small sample sizes.
2.4 Simulation Studies
We conducted extensive simulation studies to compare AMOL with existing approaches using the
value function (reward) of the estimated treatment rules. Specially, we compared three methods:
(a) Q-learning based on a linear regression model with lasso penalty; (b) OWL as in [Zhao et
al., 2014]; (c) AMOL, our proposed method where weighted linear regression with lasso penalty
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was used to estimate m̂k and regular linear regression with lasso penalty was used to estimate ŝk.
When estimating conditional expectations in Q-learning, the interactions between treatment and
health history were included in the regression models. Our simulation settings imitated either a
two-stage or a four-stage trial. In the following, we report the results from the four-stage settings.
In the Appendix A, we also provide additional simulation results to demonstrate the benefits of the
single-stage (Section A.1) and two-stage AMOL (Section A.2).
In the first four-stage setting, we considered 20 feature variables simulated from a multivariate
normal distribution, where the first ten variables X1, · · · , X10 had a pairwise correlation of 0.2, the
remaining 10 variables were uncorrelated, and the variance for Xj ’s was 1. The reward functions
were generated as follows:
R1 = X1A1 +N (0, 1); R2 = (R1 +X22 +X23 − 0.8)A2 +N (0, 1);
R3 = 2(R2 +X4)A3 +X
2
5 +X6 +N (0, 1); R4 = (R3 − 0.5)A4 +N (0, 1).
The randomization probabilities of treatment assignment at each stage were allowed to depend on
the feature variables through
P (A1 = 1|H1) =
1
1 + exp(−0.5X1)




P (A3 = 1|H3) =
1
1 + exp(0.2X3)




In the second four-stage setting, we imitated a situation where the whole population consisted of
a finite number of latent subgroups for which the optimal treatment rule was the same within the
group. Specifically, we assumed that there were 10 latent groups, labeled as 1 to 10. For subjects
in group l, given a randomly assigned treatment sequence (A1, A2, A3, A4) with equal probabilities,




jl + N(0, 1), where
A∗jl = 2([l/(2j − 1)] mod 2) − 1. Therefore, for any subject from group l, the optimal treatment
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rule should be (A∗1l, ..., A
∗
4l). However, in practice, we did not observe the group label; instead, we
observed feature variables that might be informative of the latent group. In this simulation study,
the feature variables consisted of each (X1, ..., X30) from a multivariate normal distribution with
the same correlation matrix as in the previous setting. Furthermore, X1, ..., X10 had the same mean
value µl, which was a group-specific constant generated from N(0, 5), but the mean of X11, ..., X30
was zeros. In other words, only X1, ..., X10 were informative of the group label; the remaining
variables were just noise.
For each data set, we applied Q-learning, OWL, and our proposed method AMOL to estimate
the optimal rule. At each stage k, the patient’s health history Hk contained feature variables up to
stage k, treatment assignments received at all previous stages, interaction between treatment and
feature variables at each previous stage, and interim outcomes at previous stages. Additionally, a
linear kernel was used for OWL and AMOL, and the cost parameter was selected by four-fold cross
validation. For each method, the value function corresponding to the estimated optimal rule was
computed using expression (2.1) from the empirical average of a large independent test data set
with a sample size of 20, 000.
The results from 500 replicates are presented in Figures 2.1 and 2.2 and Table 2.1. In the first
setting, we observe that Q-learning incorporating lasso variable selection shows high variability of
the value function with a small sample size(n =50), but becomes significantly better with increasing
sample sizes (e.g., 200 and 400) since the true model for the reward function is based on a regression
model. Comparatively, AMOL shows a significant improvement over OWL with all sample sizes,
in terms of a larger value and smaller variability due to the data augmentation in the proposed
methods. It also outperforms Q-learning with small sample sizes (n = 50 and n = 100). In the
second setting, since the rewards are generated from a latent mixture model, the regression model
in Q-learning is very likely to be misspecified, and thus, it performs poorly under all sample sizes
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Table 2.1: Mean and median of the empirical value function for two simulation scenarios evaluated
with an independent test data.
Simulation setting 1 (optimal value 10.1)
n Q-learning OWL AMOL
Mean (Std) Median Mean (Std) Median Mean (Std) Median
50 6.786(1.119) 6.753 2.604(1.502) 2.561 5.041(1.03) 5.115
100 7.711(1.016) 6.996 3.049(1.448) 2.957 5.605(0.924) 5.642
200 8.475(0.843) 8.874 3.593(1.461) 3.486 6.343(0.847) 6.355
400 8.934(0.398) 9.034 4.566(1.265) 4.603 6.958(0.704) 6.987
Simulation setting 2 (optimal value 4)
n Q-learning OWL AMOL
Mean (Std) Median Mean (Std) Median Mean (Std) Median
50 0.042(0.182) 0.003 0.764(0.522) 0.773 1.472(0.468) 1.49
100 0.103(0.281) 0.011 0.966(0.484) 0.944 1.937(0.447) 1.932
200 0.291(0.404) 0.062 1.281(0.492) 1.284 2.459(0.365) 2.47
400 0.635(0.355) 0.717 1.638(0.446) 1.626 2.894(0.342) 2.894
(only achieving a median value of 0.717 when n = 400, compared to the actual optimal value 4).
For a proportion of the 500 replications, no treatment by covariates interaction terms were selected
by lasso regression in at least one step of Q-learning. In this case, the optimal treatment was picked
randomly to compute the value function using the testing data. Since in this setting, the optimal
treatment boundary is highly non-linear with 10 latent classes, Q-learning encounters difficulties
when selecting optimal treatment rules. AMOL outperforms OWL and Q-learning in all cases,
and achieves a median value of 2.894 for a sample size of 400. Similar comparative performances
are observed in the two-stage settings reported in the Appendix A.2.
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Figure 2.1: Simulation setting 1 with four-stage design (optimal value = 10.1)
Figure 2.2: Simulation setting 2 with four-stage design (optimal value = 4)
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2.5 Applications
Our first application is based on data related to a two-stage SMART for children affected by ADHD
[Pelham Jr and Fabiano, 2008]. Interventions being compared were different doses of metham-
phetamine (MED) and different intensities of behavioral modification (BMOD). As shown in Fig-
ure 2.3, children were randomly assigned to begin with low-intensity behavioral modification or
with low-dose medication. This stage lasted for two months, after which the Impairment Rating
Scale (IRS) and the individualized list of target behaviors (ITB) were used to assess each child’s
response to initial treatment. Children who responded continued to receive the initial low inten-
sity treatment, and children who did not respond were re-randomized to either intensify the initial
treatment or switch to the other type of treatment. The primary outcome of the study was a school
performance score measured at the end of study which ranges from 1 to 5. For the ADHD data,
there were 150 patients in total, 51 in remission after the first stage, and 99 entered second stage
randomization. The randomization probabilities were 0.5 at either stage.
Similar to the simulation studies, we compared the performance of Q-learning, OWL, and
AMOL on the ADHD data. The feature variables for the first stage included ODD (Oppositional
Defiant Disorder) Diagnosis, baseline ADHD score, race (white) and prior medication prescription.
There were two intermediate variables, months to non-response and adherence to the first stage
treatment, to be included as the feature variables for the second stage in addition to those from the
first stage. The total reward was the school performance score. Similar to the simulation study,
all regression models were fitted with linear models and lasso penalty. To handle those patients
who had remission after the first stage, we assumed that they hypothetically received the optimal
treatment in the second stage. Therefore, for each learning method, the estimation of the optimal
treatment rule and the Q-function at stage 2 were only based on the actual set of the patients who
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were randomized in the second stage; while the estimation in the first stage would make use of all
the subjects including those who had remission. Finally, for a more fair comparison among all the
methods, we randomly partitioned data into a training set and a testing set with sample size ratio
5:1. We then estimated the optimal treatment rule using each method from the training data, and
evaluated the predicted value function using the testing data. The empirical value function was
calculated from the expression (2.1), with Dk’s replaced by the estimated optimal rules.
The box plot of the value estimates from 500 replicates of randomly splitting training and testing
data is presented in Figure 2.3. The best one-size-fits-all rules yielded a score of 3.51 points for the
treatment rule beginning with BMOD and then augmenting with MED; and the worst one-size-
fits-all rule was to begin with BMOD and intensify BMOD, which yielded a value of 2.65 points.
However, AMOL achieved an average mean value of 3.82, which is higher than both OWL (3.04)
and Q-learning (3.58). To visualize the importance of each tailoring variable on the optimal DTR
estimated by AMOL and Q-learning, we present the normalized coefficients of the baseline and
stage 1 tailoring variables in Figure 2.4. Based on AMOL, the largestt baseline tailoring variable is
medication prior to enrollment, while all the other variables had negligible magnitudes. Q-learning
also reveals prior medication as the most important variable but also yields additional small effects
for some other variables. Interestingly, for stage 2, both methods identify adherence to stage 1
treatment as the most important tailoring variable. AMOL estimated optimal rule (when leaving
out variables with negligible or small magnitudes) suggests that children who do not have prior
exposure to medication before the trial should start with behavioral modification, while those who
have prior medication exposure should start with the study medication. For stage 2, children who
adhere to their initial treatment but do not respond should continue with an intensified version
of the same treatment, while children who do not adhere should augment their initial assignment
with the alternative treatment. We also analyze data from the STAR*D study [Rush et al., 2004]
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Figure 2.3: Mean and empirical standard error of the value function (school performance score,
higher score desirable) based on 500 repetitions of 2-fold cross validation using ADHD data
and the results are presented in the Online Supplementary Material.
2.6 Discussion
In this work, we propose AMOL to estimate DTRs through robust augmentation to OWL. AMOL
draws efficiency by augmenting observed rewards using proper simple regression models to improve
OWL while maintaining consistency. We theoretically prove the improved efficiency of AMOL for
K = 1 and K > 1 stages. The theoretical results show that AMOL has the same approximation
bias but improves efficiency by properly constructing weights with less variability or smaller second
moment.
The future directions of this project are discussed in Chapter 5.
Appendix A contains additional simulations for the single-stage and two-stage AMOL, and data
analysis results for STAR*D study.
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Figure 2.4: Normalized coefficients of the stage 1 tailoring variables (left panel) and stage 2 tailoring
variables (right panel) obtained by AMOL and Q-learning
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Chapter 3
Estimating the Optimal Personalized
Modality for Diagnosis
3.1 Overview
In this Chapter, we develop a method to estimate optimal personalized screening rules depending
on subject-specific characteristics to maximize their diagnostic performance (weighted combination
of sensitivity and specificity). The paper is organized as follows. In section 3.2, we propose our
method to estimate personalized diagnostic rules based on large margin classifiers (particularly,
SVM) for both paired and unpaired designs and develop a simple computation algorithm for the
optimization. Section 3.3 provides theoretical results including consistency and risk bound of the
personalized decision rule in the missing data framework. Section 3.4 presents several simulation
studies including one mimicking a real breast cancer study to demonstrate the superior performance
of the method. In Section 3.5, we analyze data from real studies on PD. Final remarks are given
in Section 3.6.
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3.2 Methods
3.2.1 Personalized diagnostic rules and performance measure
Consider a dichotomous disease outcome (D = 1: diseased and D = 0: non-diseased) and two
diagnostic modalities or screening procedures (A versus B). Let X denote a vector of subject-
specific characteristics including a subject’s risk factors, susceptibility biomarkers, or prognostic
biomarkers. Our goal is to derive a decision rule to recommend one diagnostic modality depending
on X such that for patients with feature variables X, the sensitivity of the recommended modality
is not lower than the alternative modality; while for healthy control subjects with the same feature
variables X, the specificity of the recommended modality is also not lower than the competing
modality.
Diagnostic tests are often ordinal or dimensional measures. For example, in cancer screening
studies, radiologists assess an image obtained from certain imaging modality and assign a diagnostic
score to describe the likelihood of a subject having a benign or malignant test result. For breast
cancer screening, the malignancy likelihood score, BI-RADS [BI-RADS Committee and American
College of Radiology, 1998], is obtained from breast imaging studies where a radiologist rates
a mammogram or other image into a BI-RADS score ranging from 0 to 6 (0: Incomplete, 1:
Negative, 2: Benign finding, 3: Probably benign, 4: Suspicious abnormality, biopsy recommended,
5: Highly suggestive of malignancy, biopsy recommended, 6: Known biopsy, proven malignancy).
For neuropsychiatric disorders, biological measures are explored to assist disease diagnosis[Dubois
et al., 2014; Lilienfeld, 2014].
Denote YA as the diagnostic score rated using modality A and YB rated using modality B.
Assume that YA and YB are comparable and a higher score is associated with greater likelihood of
being diseased (or malignant). In a paired design, both diagnostic scores YA and YB are observed
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for each subject. Let T (X) denote a screening rule determining the choice of modality A or B
depending on the subject-specific characteristics, X, where T (X) = 1 indicates choosing modality
A and T (X) = −1 indicates choosing modality B. That is, T (·) maps X to {1,−1}. Note that
a more sensitive modality will lead to a higher screening score for diseased subjects and a more
specific modality will lead to a lower screening score for non-diseased subjects. Thus for diseased
subjects, if YA > YB we expect an effective rule T to assign T (X) = 1 for high sensitivity; and if
YA < YB, we expect T (X) = −1. Equivalently, a desirable T should yield a large value of
E[I(YA ≥ YB)I(1 = T (X))|D = 1] + E[I(YA ≤ YB)I(−1 = T (X))|D = 1]
to achieve high sensitivity. Similarly, for non-diseased subjects, a desriable T will yield a large
value of
E[I(YA ≤ YB)I(1 = T (X))|D = 0] + E[I(YA ≥ YB)I(−1 = T (X))|D = 0]
to achieve high specificity. To consider both sensitivity and specificity when estimating T , introduce
ω0 as a pre-specified weight in [0, 1] to balance the above two objectives with a default of ω0 = 0.5
if none is preferred. The goal for finding an optimal personalized diagnostic rule is then to solve
an optimization problem:
maxT (·) [ω0 {E[I(YA ≥ YB)I(1 = T (X))|D = 1] + E[I(YA ≤ YB)I(−1 = T (X))|D = 1]}
+(1− ω0) {E[I(YA ≤ YB)I(1 = T (X))|D = 0] + E[I(YA ≥ YB)I(−1 = T (X))|D = 0]}] . (3.1)
One potential limitation of this objective function is that the derived rule does not differentiate
between subjects with YA much larger than YB from subjects with only slightly greater YA compared
to YB. A solution is to incorporate the difference between diagnostic scores under two modalities
into the classification rule in 3.1. Specifically, define Z = |YA−YB| and we aim to solve the following
objective function
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maxT (·)[ω0 {E[ZI(YA ≥ YB)I(1 = T (X))|D = 1] + E[ZI(YA ≤ YB)I(−1 = T (X))|D = 1]}
+(1− ω0) {E[ZI(YA ≤ YB)I(1 = T (X))|D = 0] + E[ZI(YA ≥ YB)I(−1 = T (X))|D = 0]}]. (3.2)
Since I(−1 6= T (X)) = 1− I(1 6= T (X)), criterion 3.1 and 3.2 can be unified as
min
T (·)
E[WI(V 6= T (X))], V = (2D − 1)sign(YA − YB), (3.3)
where W = ωD + (1 − ω)(1 − D) for 3.1 and W = [ωD + (1 − ω)(1 − D)]Z for 3.2. Here,
ω = (ω0/p)/[ω0/p + (1 − ω0)/(1 − p)], where p is the disease prevalence. The decision rule that
minimizes 3.3 is referred as the optimal personalized diagnostic rule, which we denote as T ∗. In
the following sections, we will propose methods to estimate T ∗ under paired and unpaired design.
3.2.2 Estimation under a paired design
When diagnostic tests do not interfere with each other and when feasible, paired design is used [Pepe
et al., 2003], where each subject is administered with both tests. Paired design minimizes between
subjects variation in the estimation and eliminates the possibility of confounding. Therefore it
provides more efficient assessment and valid comparison of the performance of each test. Specifically,
in a paired diagnostic study, patients and controls are recruited and each subject receives two
diagnostic modalities (or diagnostic tests), Ai and Bi. Radiologists blinded to the disease status
give rating scores (e.g. BIRADS scores), YAi and YBi, respectively, to assess the likelihood of a





WiI(Vi 6= T (Xi)), Vi = (2Di − 1)sign(YAi − YBi), i = 1, ..., n, (3.4)
where Wi = ωDi+(1−ω)(1−Di) for (1,) Wi = [ωDi+(1−ω)(1−Di)]Zi for 3.2, and Zi = |YAi−YBi|.
Direct minimization of 3.4 is a difficult problem due to the discontinuity of the indicator function.
However, the objective function in 3.4 is in fact the empirical weighted misclassification error rate
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in a classification problem treating Vi as class labels, Xi as feature variables, and each subject being
weighted by Wi. Many machine learning techniques can be applied to find the optimal rule T ∗.
Particularly, we choose large-margin-based classifiers due to their successful applications in many
fields. Let f(x) be a diagnostic decision function associated with the classification rule T , i.e.,
T (x) = sign(f(x)), and define L(υf) as a large margin-based loss function, for example, hinge loss







WiL(Vif(Xi)) + λn‖f‖2H, (3.5)
where λn is a pre-specified tuning parameter, H is a normed space for which f belongs to, and
‖f‖H is the norm or the semi-norm defined in H. Examples of H include a linear space consisting
of α+βTx and the ‖f‖H is the Euclidean norm of β, or a reproducing kernel Hilbert space (RKHS)
based on some kernel function K(·, ·), and ‖f‖H is the norm defined in this RKHS.
The optimization problem in 3.5 can be carried out via its dual problem. Following the KKT












αiαjViVj < Xi, Xj > (3.6)
subject to constraints 0 ≤ αi ≤ CnWi, i = 1, ..., n and
∑n
i=1 αiVi = 0, where Cn is the tuning
parameter associated with λn. Here, < Xi, Xj > is the inner product defined in the space H: if
H consists of linear function, then < Xi, Xj >= XTi Xj ; if H is the RKHS embedded with kernel
function K(·, ·), then < Xi, Xj >= K(Xi, Xj). For the latter, the most commonly used kernel
function is the Gaussian kernel where K(x, y) = exp{−‖x − y‖2/σ2n} and σ2n is the bandwidth
tuned using data. Because the optimization 3.6 only involves the inner product of Xi and Xj ,
the computational cost is related to the sample size n instead of the dimensionality of X. Thus,
the high-dimensionality of X is no longer an issue in the kernel-based method. Computationally,
CHAPTER 3. ESTIMATING THE OPTIMAL PERSONALIZED MODALITY FOR
DIAGNOSIS 56
3.6 can be solved by quadratic programming algorithms, and the tuning parameter Cn (and σ
2
n if
Gaussian kernel is used) is selected using cross-validation.
When there are multiple radiologists providing rating scores for each modality, a simple method
to incorporate results from multiple readers is to consider the average performance over the readers.









where N is the number of readers and Wik and Vik are the corresponding weights and class labels
defined for each subject i and reader k.
3.2.3 Estimation under an unpaired design
In many other diagnostic studies, subjects may not undergo multiple modalities due to interference,
tests having significant risk, high cost, or infeasible [Pepe et al., 2003]. In these cases, an unpaired
design is used where one group of subjects receive diagnostic modality A and the other matched
group of subjects receive diagnostic modality B. Under an unpaired design, directly comparing the
diagnostic performance of A and B on the same subject is no longer feasible. Since subjects may
receive only one of the two modalities, we introduce random variable M to denote the modality that
the subject actually receives, where M = 1 indicates receiving A and M = −1 indicates receiving B.
Let Y be the observed rating score which is YA if M = 1 and YB if M = −1. Since in an unpaired
design each subject has only one outcome (YA or YB) observed, the minimization in 3.3 cannot be
directly implemented using the observed data. To estimate the optimal personalized diagnostic rules
using the unpaired data, we require missing at random (MAR) condition, (C.1): YA, YB and M are
independent given X and D. The implication of (C.1) is that a subject’s modality assignment M
in a diagnostic study is conditionally independent of their missing rating score given their observed
feature variables X, disease status, and observed rating score. This condition also assumes that
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the dependence among patient’s observed and unobserved rating scores YA and YB must be fully
explained by X and D. The MAR assumption (C.1) is necessary when borrowing other similar
subjects’ diagnostic scores to infer a particular subject’s missing rating score on modality A or B.
To estimate 3.3, we use similar pairs of subjects where one receives modality A but the other
receives B to approximate the terms in 3.3. Select a diseased subject (D = 1), who has feature
variables X and has a measurement YA of modality A, and another independent diseased subject
(D̃ = 1), who has feature variables X̃ and has a measurement ỸB for modality B. If X and X̃
are close, under condition (C.1) we expect a desirable decision rule should assign the first subject
to A if rating scores YA ≥ ỸB, and to B if rating scores YA < ỸB. Similarly, for a pair of non-
diseased subjects, a desirable decision rule will choose the modality with rating scores YA ≤ ỸB.
The similarity between two subjects is characterized using kernel distance kan(‖X − X̃‖) where
kan(·) is a kernel function with bandwidth an. Furthermore, since subjects may receive A or B
with different probability since modality is not randomized, we adjust for this propensity by inverse
probability weighting, where we denote π(X,D) as the probability of M = 1 (receiving modality
A) given X and D. Subsequently, for pairs of diseased subjects, a desirable decision rule T (·) will
yield a large value of
E
[
I(T (X) = sign(YA − ỸB))I(M 6= M̃,D = D̃ = 1)
×kan(‖X − X̃‖)/{π(X, 1)(1− π(X̃, 1))}
]
.
Similarly, for non-diseased pairs a desirable rule will lead to a large value of
E
[
I(T (X) = −sign(YA − ỸB))I(M 6= M̃,D = D̃ = 0)
×kan(‖X − X̃‖)/{π(X, 1)(1− π(X̃, 1))}
]
.
As in a paired design, introducing ω0 as a weight for balancing sensitivity and specificity, we aim to
maximize a weighted summation of the above two terms. Furthermore, to incorporate the difference
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of the observed scores, we can include the magnitude of |YA − ỸB| in the above expectation and
define weights ω as in the paired design.
To summarize, we maximize
E
[
Q(O, Õ)I(T (X) = (2D − 1)sign(YA − ỸB))kan(‖X − X̃‖)




where O = (YA, X,D), Õ = (ỸB, X̃, D̃), O and Õ are independent. Note here
p(M,X,D) = I(M = 1)π(X,D) + I(M = −1)(1− π(X,D),
and Q(O, Õ) = ωD + (1 − ω)(1 −D) if one does not weight by the difference on observed scores,




Q(O, Õ)I(T (X) = (2D − 1)sign(YA − ỸB))kan(‖X − X̃‖)







Q((YA, X,D), (ỸB, X̃, D̃))I(T (X) = (2D − 1)sign(YA − ỸB))kan(‖X − X̃‖)
× I(M 6= M̃,D = D̃)
p(M,X,D)p(M̃,X, D̃)




Q((YA, X,D), (ỸB, X̃, D̃))I(T (X) = (2D − 1)sign(Y − Ỹ ))kan(‖X − X̃‖)I(D = D̃)
]
,
where the last step uses the MAR assumption in (C.1). Moreover, when an converges to zero, the
last term approximates the following quantity up to some constant
E
[
Q((YA, X,D), (ỸB, X,D))I(T (X) = (2D − 1)sign(YA − ỸB))
]
,
which is equivalent to
E [Q((YA, X,D), (YB, X,D))I(T (X) = (2D − 1)sign(YA − YB))] .
This follows by the conditional independence of YA and YB given (X,D) and the fact that ỸB is an
independent copy of YB. Note that Q((YA, X,D), (YB, X,D)) = ωD + (1− ω)(1−D), if one does
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not weight by |YA − YB|; and it is Q((YA, X,D), (YB, X,D)) = |YA − YB| {ωD + (1− ω)(1−D)},
if one does. By the definition of W in Section 3.2, the maximization becomes
max
T (·)
E [WI(T (X) = sign(YA − YB)(2D − 1))] = max
T (·)
E [WI(T (X) = V ] ,
which is exactly the same optimization problem as in 3.3. This justifies using 3.7 to find the optimal
diagnostic rule.







Q(Oi, Oj)I(T (Xi) = Vij)kan(‖Xi −Xj‖)
I(Mi 6= Mj , Di = Dj)
p̂(Mi, Xi, Di)p̂(Mj , Xj , Dj)
]
,
where Vij = (2Di− 1)(2I(Mi = 1)− 1)sign(Yi− Yj), and p̂(M,X,D) is an estimator of p(M,X,D)
by regressing M on (X,D). These propensity scores are obtained by logistic regression or other
machine learning approaches. Again, due to the difficulty of optimization involving an indicator










I(Mi 6= Mj , Di = Dj)




Similar to the paired design case, weighted support vector machine can be used to find the best
rule T ∗(x) = sign(f∗(x)) when L(·) is the hinge loss.
3.3 Theoretical Properties
In this section, we provide theoretical justification of the proposed optimal rule. We denote the
expression 3.3, E[WI(V 6= T (X))], as R(f) when T (X) = sign(f(X)). Since
E[WI(V 6= T (X))] = E {E[WI(V = −1)|X]I(T (X) = 1) + E[WI(V = 1)|X]I(T (X) = −1)} ,
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it is easy to see that the Bayes decision rule is given by
T ∗(X) = sign(f∗(X)), f∗(x) = E[WI(V = 1)|X = x]− E[WI(V = −1)|X = x].
We further define RL(f) = E[WL(V f(X))] for a large margin loss L(·). Then it is clear that
our estimated rule minimizes the empirical version of RL(f) for the paired design and minimize
an approximated empirical version of RL(f) in the unpaired design. Therefore, it is natural to
ask whether the minimizer of RL(f) also minimizes R(f). Our first theorem gives this Fisher
consistency and compares the approximation error due to using RL(f).
Theorem 3.3.1. If f̃ minimizes RL(f), then T ∗(x) = sign(f̃(x)). Furthermore, for any f ,
R(f)−R(f∗) ≤ RL(f)−RL(f̃).
The proof of Theorem 3.3.1 follows from Proposition 3.1 and Theorem 3.2 in [Zhao et al., 2012]
by treating V as the treatment assignment in their context, and thus omitted here.
Our next two theorems provide convergence rates for R(f̂) −R(f∗), where f̂ is the estimated
decision function by minimizing 3.5 for the paired design and 3.8 for the unpaired design when
L(z) = (1 − z)+ and H is chosen to be the RKHS associated with the Gaussian kernel with
bandwidth 1/σn. The particular choice of H is due to the fact that any L2-integral function can be
well approximated by the function in H if σn is chosen to be large enough [Steinwart and Scovel,
2007]. To state the convergence rate, we need the so-called geometric noise assumption for the





≤ Ctqd/2, t > 0,
where q is a constant in (0,∞), d is the dimension of X, and ∆(x) is the distance of x to the
region {x′ : f(x)f(x′) < 0}. This condition is used in [Steinwart and Scovel, 2007] to derive the
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convergence property for the support vector machine. Some examples of q are given in [Steinwart
and Scovel, 2007] . Our next Theorem 3.3.2 gives the asymptotic property of f̂ for the paired
design.
Theorem 3.3.2. In a paired design, let f̂ minimize 3.5 in H. Suppose σn = λ−1/(q+1)dn . Then for
any δ > 0, 0 < ν < 2, there exists a constant c(ν, δ, d) such that
P (R(f̂) ≤ R(f∗) + ε) ≥ 1− e−τ ,









with c1 = 2/(2 + ν) + (2 − ν)(1 +
δ)/[(2 + ν)(1 + q)]. Furthermore, if we choose λn = n
−c2 where c2 = 2(1 + q)/([(4 + ν)q + 2 + (2−
ν)(1 + δ)], then R(f̂n)−R∗ = Op(n−c2q/(1+q)).
Theorem 3.3.2 shows that with proper choice of the bandwidth for the Gaussian kernel for H,
the convergence rate of the risk for f̂n, as compared to the Bayes risk, is of a polynomial order in
n. The proof Theorem 3.3.2 follows exactly the same arguments as proving Theorem 3.4 in [Zhao
et al., 2012], where their R is equivalent to our W and their A is equivalent to our V . Thus we
skip the proof.
We now consider the unpaired design. We note the difference between 3.8 and 3.5 is the kernel
approximation
ĝ(O; f) = n−1
n∑
j=1
Q(O,Oj)L(Vijf(X))kan(‖Xi −Xj‖)I(M 6= Mj , D = Dj)/p̂(Mj , Xj , Dj).
Then f̂ , which minimizes 3.8, minimizes
min
f∈H
Pnĝ(O; f) + λn‖f‖2,
where Pn denotes the empirical measure. Thus, to establish the convergence rate of R(f̂), it is
necessary to examine the approximation of ĝ(O) to WL(V f) which depends on the kernel approx-
imation using kan(·). This gives the following theorem.
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Theorem 3.3.3. Under the same conditions in Theorem 3.3.2 and the same choices of λn and σn, if
we further assume the conditional density of X given (M,D, Y ) is twice-continuously differentiable
and kan(·) = a−1n k(x/an) with k(·) being a kernel function symmetric with respect to 0, furthermore,
supO |p̂(O)− p(O)| = Op(n−γ) for some γ > 0 and infO p(O) > 0, then it holds
R(f̂n)−R(f∗) = Op(n−c2 + n−γ + (nadn/ log n)−1/2 + a2n),
where c2 is a constant depending on (q, ν, δ).
The condition regarding p̂(O) in Theorem concerns with the accuracy in estimating the propen-
sity score. Particularly, if a parametric model is used to estimate p(O) consistently, it is clear
γ = 1/2.
Proof. First, from the fact
Pnĝ(O; f̂) + λn‖f̂‖2 ≤ Pnĝ(O; f∗) + λn‖f‖2,
we have
‖f‖2 ≤ O(1) + sup
O
|ĝ(O; f∗)|/λn.
By the uniform convergence of kernel approximation (c.f., [Hansen, 2008]), supo |ĝ(o; f∗)| = O(
√
log n/(nan)d+
a2n). Therefore, we obtain a preliminary upper bound of
‖f̂‖ ≤ O(λ−1/2n ),
which is also an upper bound for the L∞-norm of f̂ by the embedding property of H.
Next, the same proof as Theorem 1 gives
R(f̂n)−R(f∗) ≤ E[WL(V f̂)q(X)]− E[WL(V f∗)q(X)],
where q(X) is the marginal density of X. Then using the fact that f̂ minimizes 3.8, we have
2(R(f̂n)−R(f∗)) ≤ 2(E[WL(V f̂)q(X)]− E[WL(V f∗)q(X)])
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≤ −{Pn −P} ĝ(O; f̂)− λn‖f̂‖2 + {Pn −P} ĝ(O; f∗) + λn‖f∗‖2
+P
{
ĝ(O; f̂)− 2WL(V f̂)q(X)
}




{Pn −P}ĝ(O; f) + λn (3.9)
+P
{
ĝ(O; f̂)− 2WL(V f̂)q(X)
}
+ P {ĝ(O; f∗)− 2WL(V f∗)q(X)} . (3.10)
For the first term in 3.10, we note that ĝ(O; f) is Lipschitz continuous in f and accord-
ing Theorem 2.1 in [Steinwart and Scovel, 2007], the entropy for the unit ball of H is of order
O(σ
(1−ν/2)(1+δ)d
n ε−ν). Therefore, using the large deviation results for the empirical process (Theo-
rem 2.14.10, [Van Der Vaart and Wellner, 1996]), we conclude that this term is
sup
f∈H,‖f‖≤λ−1/2n
{Pn −P}ĝ(O; f) = Op(λ−1/2n n−1/2σ(1−ν/2)(1+δ)d/2n ).
For the last two terms in 3.10, we again apply the uniform approximation property to ĝ(O; f̂) plus
the approximation p̂(O) to obtain




Q(O, Õ)L((2D − 1)sign(Y − Ỹ )f̂(X))I(M 6= M̃,D = D̃)
p(O)p(Õ)







log n/(nan)d + a
2
n).






Q(O, Õ)L((2D − 1)sign(Y − Ỹ )f̂(X))I(M 6= M̃,D = D̃)
p(O)p(Õ)





















log n/(nan)d + a
2
n).
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Similarly,
Pĝ(O; f∗) = 2E [WL(V f∗(X))q̂(X)] +Op(n−γ +
√
log n/(nan)d + a
2
n).
Combining these results, we obtain
R(f̂n)−R(f∗) ≤ Op(λ−1/2n n−1/2σ(1−ν/2)(1+δ)d/2n + λn) +Op(n−γ +
√
log n/(nan)d + a
2
n).
Theorem 3 thus holds from the choice of λn and σn in Theorem 2.
3.4 Numeric Studies
3.4.1 Simulations Under Paired Design
In a paired design, we observe both modalities A and B for all the subjects. We simulate a sample
size of 100 subjects (n = 100), half of the subjects are diseased (Di = 1) and the other half
are non-diseased (Di = 0). We compare ROCs and AUCs produced by different methods on an
independent test set of 10, 000 subjects and 100 replications of training data sets. For each subject
i with disease status Di = d, we generate Xi = (X1i, ..., Xpi) from a uniform distribution on [0, 1].
We then generate their diagnostic rating scores as
ỸAi = 0.2I(Di = 1) + 2I(X1i > 0.5)I(Di = 1) + εAi,
ỸBi = 0.3I(Di = 1) + 2I(X1i < 0.5)I(Di = 1) + εBi, (3.11)
where (εAi, εBi) follows a bivariate normal distribution with mean zero, and we consider two cases
for the covariance matrix of error terms for ỸA and ỸB: independent case where Σ = [ 1 00 1 ] so that
assumption C.1 holds and correlated case where Σ = [ 1 0.50.5 1 ] for sensitivity analysis. Next, we
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obtain the rating scores under modalities A and B as
YAi = 1 + I(ỸAi ≥ 0) + I(ỸAi ≥ 0.5) + I(ỸAi ≥ 1) + I(ỸAi ≥ 1.5),
YBi = 1 + I(ỸBi ≥ 0) + I(ỸBi ≥ 0.5) + I(ỸBi ≥ 1) + I(ỸBi ≥ 1.5). (3.12)
Then we apply the proposed methods to determine the optimal personalized diagnostic rules.
We compare a few methods of modality assignment in terms of their ROC curves and AUC. The
first two are “one-size-fits-all” rules where all subjects receive modality A or all subjects receive
modality B. The next one is to estimate the optimal personalized rule depending on a subject’s
covariates X without weighting by the magnitude of the difference of screening score on A and B,
wSVM1: use Wi = ωDi + (1− ω)(1−Di) in 3.3 to obtain the optimal rule.
The last method is to estimate the optimal personalized rule considering the magnitude of the
difference screening scores:
wSVM2: use Wi = [ωDi + (1− ω)(1−Di)]|YAi − YBi| in 3.3 to obtain the optimal rule.
The results comparing diagnostic performance of (a) all receives modality A; (b) all receives
modality B; (c) each subject receives modality chosen by wSVM1; and (d) each subject receives
modality chosen by wSVM2 are reported in Table 3.1 and Figure 3.1. Table 3.1 summarizes the
empirical AUCs and standard deviations across 100 replications of analyses (a) through (d) under
several choices of ω while Figure 3.1 shows the average ROC curve. The proposed personalized
diagnostic rule method performs similarly regardless of whether condition (C.1) holds or not (inde-
pendent rating scores or correlated scores). When ω = 0.5 and 0.75, wSVM1 and wSVM2 increased
the empirical AUC by about 5%. Although the average ROC curve of modality A and B are quite
close, using ω = 0.5 or 0.75, the proposed optimal personalized rule assigning modality according to
subject-specific covariates improves sensitivity and specificity at all thresholds compared to assign-
ing all subjects to either A or B. Comparing wSVM1 and wSVM2, they have similar performance
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except for ω = 0.25. In practice, the choice of ω depends on the relative importance of sensitivity
and specificity in the target population where the diagnostic tool will be used. If no such prior
information is available, a common choice is ω = 0.5.
Additional simulation results of unpaired design are provided in the Appendix B.1, where the
results are similar to the paired design.
3.4.2 Simulation 2: a Breast Cancer Study
In this setting, we imitate a breast cancer screening study with paired modality measures [Pataky
et al., 2013], where we compare mammography the combined screening using both mammography
and MRI. Several covariates are considered: X1 is a subject’s age where older age is associated
with a greater risk for breast cancer; X2 is BRCA1 or BRCA2 mutation status where carriers
of either mutation will have a greater risk; X3 is the density of breast where it is more difficult
to use mammography alone to detect tumor for denser breasts. Age, mutation status and breast
density are observed subject-specific covariates. In our simulation settings, we simulate MRI to
be more sensitive to detect smaller tumor, and mammography to have the same sensitivity but
higher specificity for larger tumor. To be more realistic, we also simulated tumor size (X4) as an
additional unobserved variable to be associated with breast cancer risk but not available at the
screening stage without biopsy, and we assumed X4 to be increasing with age. In this simulation
scenario, all covariates X1 through X4 influence a radiologist’s ability to rate a tumor sample.
Detailed simulation scheme and empirical AUC are provided in the Appendix B.2.
Sensitivity, specificity and classification accuracy are presented in Table C.1. Using mammog-
raphy alone on all subjects has a lower sensitivity (84.2%) and higher specificity (99.5%), and
combining mammography and MRI increases the sensitivity to 99.6% with a reduced specificity
of 89.7%. The personalized assignment of modality (either mammography alone or combined) us-
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(a) w = 0.25 ROC Independent

















(b) w = 0.25 ROC Correlated

















(c) w = 0.50 ROC Independent

















(d) w = 0.50 ROC Correlated

















(e) w = 0.75 ROC Independent

















(f) w = 0.75 ROC Correlated
Figure 3.1: Average ROC for Paired Design with independent and correlated modality measure-
ments within patients
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ing our proposed method wSVM1 and wSVM2 increases the sensitivity to be close to modality
B (98.5%) without sacrificing specificity (94.1% and 94.2%). Thus it reduces the overall miss-
classification rate from 8.30% for mammography alone and 5.24% for mammography and MRI
combined to 3.64% and 3.61%, respectively.
To demonstrate the interpretability of our proposed method, the linear rule estimated in one
replication is f(X) = 1.21 − 0.47X1 − 0.38X2 − 0.97X3 for wSVM1 and f(X) = 1.23 − 0.43X1 −
0.33X2−0.98X3 for wSVM2. The fitted rule recommends the more sensitive combined test of MRI
and mammography to older subjects with BRCA1 or BRCA2 mutation due to their higher risk
of breast cancer. The negative coefficient for X3 suggests subjects with denser breast tissues are
more likely to benefit from the combined test since the tumors may be harder to be detected using
mammography alone. In contrast, for younger subjects without BRCA mutations and with thinner
breast tissues, using mammography alone may be optimal.
3.5 Real Data Example: a Parkinson’s Disease Study
In this section, we analyze data collected from a Parkinson’s disease (PD) imaging study [Huang et
al., 2013]. PD is a disabling neurodegenerative disorder diagnosed on the basis of cardinal motor
features, including asymmetric bradykinesia, rigidity, and tremor [Rodriguez-Oroz et al., 2009]. In
addition to motor impairment, clinically important non-motor symptoms such as anxiety, depres-
sion, apathy, and cognitive dysfunction frequently occur and have a major impact on quality of
life [Emre, 2003]. Recent research on PD diagnosis is shifting from relying on clinical symptoms
to predicting PD at risk status before onset of clinical symptoms using biomarkers [Jankovic and
Sherer, 2014]. There has been considerable interest in evaluating the potential of advanced non-
invasive neuroimaging techniques, such as positron emission computed tomography (PET), and
magnetic resonance imaging (MRI) to provide objective measures of dysfunction in PD, thereby
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enabling accurate diagnosis, predicting disease onset, and monitoring disease progression [Huang et
al., 2008]. Previous study revealed a specific metabolic pattern that was associated with the diag-
nosis of PD from [18F]-fluorodeoxyglucose (FDG)-PET images, which involved significant elevated
brain metabolism in bilateral posterior lentiform nucleus and posterior cingulate, and metabolic
reductions in bilateral temporo-parietal association cortex in PD as compared to matched controls
[Huang et al., 2013]. In addition, diffusion tensor imaging (DTI) MRI showed significantly increased
mean diffusivity (MD) values in the posterior cingulate and decreased fractional anisotropy (FA)
values in the white matter, which were both associated with memory deficits in PD, as assessed by
California Verbal Learning Test.
Given the heterogeneous nature of PD and the course of disease progression varies among
different individuals, it is important to develop methods for personalized recommendation to assist
diagnosis of PD based on individual risk factors. Our proposed methods are used to explore
subgroups of PD patients whose measures from FDG-PET might be a better screening marker
compared with DTI. A total of 29 PD non-demented patients (H&Y: 1-3) and 23 controls matched
for age, gender, and educational level underwent MRI examination, which included high resolution
structural MRI.
Imaging examinations and neuropsychological assessments for each participant were completed
within a one-month time period. Imaging of PD subjects was performed in the practically-defined
off state, after antiparkinsonian medications had been withheld for 12 hours. Subjects with PD
underwent a full Unified Parkinsons Disease Rating Scale (UPDRS) [Fahn and Elton, 1987] ex-
amination performed by a neurologist. Mood and behavior were measured in terms of depressive
symptoms with the Beck Depression Inventory-II [Beck et al., 1996]. The diagnosis of PD was
made according to United Kingdom Brain Bank criteria [Hughes et al., 1992].
In our analysis, subject-specific covariates being considered include BDI score for depression,
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BAI score for anxiety, UPDRS motor symptoms categorized at 50%th, 75%th and 90%th quartiles,
and we controlled for demographic variables such as age, gender and years of education. All feature
variables were standardized before applying the proposed methods. One requirement for applying
wSVM is that YA and YB are on the same scale and thus comparable. In the PD study, the
imaging measures may not be on the same scale. Thus, we considered a rank-based measure by
using percentiles obtained from the empirical distribution functions for each subject as YA and YB.
Similar procedure is used in [Donohue et al., 2014] to compare biomarkers measured on the different
scales. Our analysis sample includes both paired and unpaired data. There are 32 patients (19
cases and 13 controls) on whom both image modalities were measured and with no missing data
on the feature variables. There are 34 subjects who have only one modality, where 16 subjects (7
cases) have only MRI measures, and 18 subjects (11 cases) have only PET measures.
We first show an example using paired data. We compare fractional anisotropy (FA) in white
matter and metabolic rate in the parietal lope (PAR). The empirical AUC for the fitted diagnostic
rule is computed by the leave-one out cross-validation. Comparing two one-size-fits-all rules, the
empirical AUC is 89.9% if using FA as a PD diagnostic measure on all subjects and 71.7% if using
PAR, indicating FA is preferable. To fit a personalized diagnostic rule, we examine both weighted
and unweighted schemes. Considering all 7 aforementioned covariates, wSVM2 chooses FA as the
better screening modality for all subjects and gives the empirical AUC of 89.9%, while wSVM1
choose FA for all but 2 subjects, and gives an empirical AUC of 88.1%. If excluding UPDRS, both
wSVM schemes will choose the superior screening method, FA, for all subjects. The ROC curves
are shown in Figure 3.2a. In terms of the fitted diagnostic function, the intercepts for wSVM1 is
0.29, and 0.22 for wSVM2, and the coefficients for the feature variables are negligible (on the scale
of 10−5), indicating none of the feature variables distinguishes the diagnostic ability between FA
and PAR, and thus there is no clear subgroup for which one modality outperforms the other. In
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this paired data analysis, we demonstrated that when there is a universally superior modality (in
this case, FA) and no subgroup for which the alternative modality improves performance can be
found, the proposal method will choose the modality with superior performance.
Next, we show an example of unpaired data analysis. Here we compare the mean diffu-
sivity (MD) measure in the posterior cingulate obtained from DTI-MRI and metabolic rate in
the lentiform nucleus obtained from FDG-PET. The empirical AUC is presented in Figure 3.2b.
Comparing two one-size-fits-all rules, MD at posterior cingulate on the unpaired sample has an
AUC= 87.3% and the metabolic rate at the lentiform nucleus has an AUC= 57.1%. The same
feature variables as the paired data analysis are used to fit personalized diagnostic rules. Here,
we used a triangular kernel with a bandwidth of 3 selected from cross-validation. We see wSVM1
produced a diagnostic rule with a higher AUC than using MD alone. It achieves an AUC of 93.7%
compared to 87.3% of using MD alone.
The coefficients of the fitted diagnostic rule are presented in Table 3.3. The MD is measured
in the posterior cingulate area located at the cingulate cortex. This area is related to emotion
and memory. Thus subjects with higher anxiety score (adjusting for other covariates) may be
potentially associated with higher deterioration in posterior cingulate area. Thus MD measured
in this area may be a more sensitive measure for PD patients showing more emotional symptoms
(e.g., higher anxiety score) and less motor symptoms. Since deterioration in lentiform nucleus is
related to motor impairment, for PD patients with more motor symptoms (e.g., with higher UPDRS
percentile score) and less anxiety symptoms, metabolic rate at the lentiform nucleus may be a more
sensitive measure. In this analysis, we demonstrate that examining personalized diagnostic rules
has the potential to identify subgroups suitable for applying different diagnostic measures, and
thus provides insights on comparative effectiveness of alternative modalities for clinical researchers.
Due to the small sample size and exploratory feature of the analyses, a larger sample is needed to
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confirm these suggestive findings.
3.6 Discussion
In this work, we proposed a data-driven approach to estimate optimal personalized diagnostic rule
that may depend on subject-specific characteristics such as individual risk factors, biomarkers or
subject preference. By drawing a connection with machine learning techniques, the approach can
easily handle high-dimensional biomarkers and enjoys robustness of nonparametric decision rules
and flexible nonlinear boundaries. The fitted diagnostic rule maximizes a weighted sum of sensitivity
and specificity with a user-specified weight. Our theoretical studies examine convergence rate of the
fitted decision rule to the true optimal rule. Simulation studies and real data example demonstrate
superior performance of the individualized rules in some cases compared to the “one-size-fits-all”
rules where all subjects receive the same modality.
Table 3.1: Mean (SD) for Empirical AUC for paired design (with independent and correlated
modality measurements within patients)
ω modality A modality B wSVM1 wSVM2
Independent Correlated Independent Correlated
0.25 0.692 0.694 0.646(0.044) 0.63(0.046) 0.691(0.015) 0.694(0.013)
0.5 0.692 0.694 0.748(0.047) 0.741(0.048) 0.722(0.040) 0.729(0.046)
0.75 0.692 0.694 0.736(0.044) 0.749(0.048) 0.744(0.049) 0.752(0.051)
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Table 3.2: Sensitivity and Specificity for Breast Cancer Simulation
Sensitivity Specificity Mis. Rate†
mammography 0.842 0.995 8.30%
mammography+MRI 0.996 0.897 5.24%
wSVM1 0.985 0.941 3.64%
wSVM2 0.985 0.942 3.61%
†: Missclassification rate
Table 3.3: Coefficients of the fitted diagnostic rule for the unpaired PD study
Method Int. Education Age Gender BDI BAI UPDRS50% UPDRS75% UPDRS90%
wSVM1 0.2878 -0.0565 -0.6185 -0.1536 -0.1917 0.8797 -0.0497 -0.1674 0
wSVM2 (×10−4) 294.1 -0.18 -0.23 0.33 0.32 0.47 0.26 -0.007 0
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(a) ROC for Paired Analysis of FA and Par
(b) ROC for Unpaired Analysis of MD and Lenti
Figure 3.2: ROC curve for brain imaging study for Parkinson’s Diseases
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Chapter 4
Multiple Imputed Randomized Lasso
4.1 Overview
In this chapter, our goal is to develop a method to perform variable selection for studies similar to
Project EAT where the number of predictors is large (possibly larger than the sample size), some
predictors are highly correlated, and there is substantial missingness with complicated arbitrary
missing data patterns. This chapter organized as following. We introduce the proposed multiple
imputation random lasso method in section 4.2. Results of extensive simulation studies are pre-
sented in section 4.3, where comparison is made between the performance of our proposed method
with competitors such as MILS. We apply the proposed methods to analyze project EAT data in
section 4.4 and conclude with a short discussion in section 4.5.
4.2 Multiple Imputation Random Lasso (MIRL)
4.2.1 Rationale and algorithm
Here we develop a new method, Multiple Imputation Random Lasso (MIRL), which combines mul-
tiple imputation and random lasso [Wang et al., 2011a]. Random Lasso is shown to have advantages
dealing with highly-correlated predicting variables in variable selection and prediction [Wang et al.,
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2011a]. In a nutshell, MIRL performs simultaneous parameter estimation and variable selection
across bootstrap samples of multiply imputed data sets. The final parameter estimates are aggre-
gated across samples and important variables are chosen and ranked according to stability selection
criterion [Meinshausen and Buhlmann, 2010]. To accommodate highly correlated variables, we in-
corporate similar strategy as random lasso [Wang et al., 2011a] where for each bootstrap sample,
half of the variables are used for variable selection. The developed approach can handle arbitrary
non-monotone missing pattern under the missing at random (MAR) assumption and accommodate
p > n case. There are a few new features of MIRL. First, MIRL extends random lasso to deal
with data with missing entries by multiple imputation. Second, it improves the hard thresholding
in random lasso by stability selection to yield higher prediction accuracy, better variable selection
performance, and produce an importance ranking of the variables. The procedure shares some
similarities with random forest regression [Breiman, 2001] where multiple models are fitted and a
final model is obtained through aggregation.
MIRL has four steps. In the first step, multiple imputation is performed to generate several
sets of imputed data. In the second step, bootstrap samples are obtained for each imputed data
set and an importance measure is created for each variable. In the third step, lasso-OLS estimates
are produced for bootstrapped data sets where variables are sampled from importance measures.
In the fourth step, final estimators are obtained through aggregation and use stability selection to
get a final sparse model. The MIRL algorithm is presented below and illustrated by a flowchart in
Figure 4.1, with implementation details of each step are described in section 3.2.
MIRL algorithm:
Start with a sample of n observations and p predictors with missing entries. As an example, we
consider the linear model Y = β0 +Xβ + ε, where Y denotes a continuous response variable, X is
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a n× p design matrix, and ε is the random error. The parameter of interest is β = (β1, β2, . . . , βp).
1. Let m denote the number of imputations. Impute the sample m times by chained equations
[Azur et al., 2011]. And standardize all variables to have mean 0 and variance 1.
2. For each imputed data set, generate B bootstrap samples and compute importance measures
of predictors as follows:
(a) For the bth bootstrap sample in the ith imputation, b ∈ {1, . . . , B}, apply lasso-OLS to
obtain estimates β̂
(b)
ij for βj , where i = 1, . . . ,m and j = 1, . . . , p.










3. Compute the initial MIRL estimates:
(a) For the bth bootstrap sample, randomly select dp/2e candidate variables with selection
probability of xj proportional to its importance measure Ij . Let Λ be a grid of K expo-
nential decaying sequence of tuning parameters λ’s, apply lasso-OLS to obtain estimates
β̂
(b)
ijλ for βj , j = 1, . . . , p and λ ∈ Λ.











where λib is the tuning parameter chosen by cross validation and β
(b)
ijλib
= 0 if varaible j
is not sampled.
4. Compute selection probability and MIRL estimates with stability selection:
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(b) Selection probability is given by maxλ∈Λ Π̂
λ
j .
(c) The important variables are those in the stable variable set:
Ŝstable = {j : max
λ∈Λ
Π̂λj ≥ πthr}, (4.1)
and the probability threshold πthr is chosen by cross validation with the one-standard
error rule [Hastie et al., 2005].
(d) The final MIRL estimates are defined as
β̂j = β̂
init
j × I{j ∈ Ŝstable}.
The lasso-OLS estimator [Efron et al., 2004; Belloni and Chernozhukov, 2013] in the second and
third step of the algorithm is a two-step procedure. First, we compute the lasso estimator β̂ =
arg min ‖y −Xβ‖22 + λ‖β‖1, where the tuning parameter λ is chosen from cross validation. Next,
the lasso-OLS estimator is the ordinary least squares (OLS) estimator obtained by regressing the
outcome on the subset of variables chosen by lasso. [Belloni and Chernozhukov, 2013] showed that
lasso-OLS has the advantage of smaller bias compared to the original lasso.
4.2.2 Implementation details
We now describe some details on the implementation of the algorithm in each step. In Step 1,
multiple imputation is performed. Under the MAR assumption, we impute data through the
multivariate imputation by chained equations (MICE) [Azur et al., 2011]. As initial values, MICE
imputes every missing value of a variable by the mean of observed values or a simple random draw
from the data. Next, missing values on one particular variable are imputed by the predicted values
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from a suitable regression where the predictors are all other variables (penalized regressions can be
applied for high dimensional cases). Cycling through each of the variables with missing constitutes
one cycle. Several cycles are repeated and the final imputations are retained as one imputed data
set. A low number of cycles (say 10 to 20) is often sufficient [Buuren and Groothuis-Oudshoorn,
2011]. Lastly, the entire imputation process is repeated to generate multiple imputed data sets. The
imputation regression models are provided for continuous data (predictive mean matching, normal),
binary data (logistic regression), unordered categorical data (polytomous logistic regression) and
ordered categorical data (proportional odds). For non-ignorable missing data, there are also some
procedures for multiple imputation. We refer the readers to [Glynn et al., 1993] and [Siddique and
Belin, 2008] for details.
In Step 2, bootstrap samples are generated for each imputed data and an importance measure
is created for each predictor variable. Specifically, for each bootstrap sample, lasso-OLS is applied
where the tuning parameter is selected by cross validation. A measure of importance for each
covariate is calculated as the absolute value of the average of coefficients across bootstrap samples
and imputations.
In Step 3, for each imputed data, MIRL applies lasso-OLS where half of the variables are
randomly selected with probability proportional to the importance measures obtained from Step 2,
and lasso-OLS is applied. We explored other choices of number of variables to sample in numerical
study, and found the result was insensitive to choices p/2 or p/3. Next, the initial MIRL estimators
are obtained by averaging random lasso coefficients across bootstrap samples and imputations.
The initial MIRL estimators, however, are not sparse. As long as a predictor is selected at least
once in a bootstrap sample, the corresponding coefficient will not be zero. A natural approach
to yield sparse model is through thresholding. The original random lasso algorithm [Wang et al.,
2011a] introduced a threshold of tn = 1/n, that is, consider a variable xj to be selected in the final
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model only when the corresponding averaged coefficient satisfies |β̂j | > tn. This threshold may
produce sparse model for situations where p  n. However for some epidemiological applications
where p < n, it sets only a few coefficients to zero. For incomplete data, it is also difficult to
determine whether n should be the sample size of the complete case data or the original data, or
some value in between. In contrast, MIRL provides a systematic way to choose the threshold.
In Step 4 , MIRL ranks the variables and determines the informative ones by stability selection
[Meinshausen and Buhlmann, 2010]. The central idea of stability selection is to refit the model
on bootstrap sampled data sets and choose variables that are most frequently selected across the
refitted models. It is sufficiently general to be applicable to many selection algorithms, and shown
to achieve consistent variable selection using lasso penalty under weak assumptions on the design
matrix [Meinshausen and Buhlmann, 2010]. Note the empirical selection probabilities in (4.1)
involves πthr as a predetermined threshold probability to be selected. Here, we use 4-fold cross
validation with an one-standard-error rule to choose selection probability threshold πthr. That is, we
obtain the threshold that minimizes the mean squared prediction error (MSPE), and set πthr as the
largest threshold whose MSPE does not exceed one standard deviation band of the minimizer. The
empirical selection probabilities, maxλ∈Λ Π̂
λ
j , are natural measures of the importance of variables.
For example, if determining the top 10 most important variables is desirable, instead of calculating
πthr, one can choose the top 10 variables with the highest selection probabilities.
4.3 Simulation Studies
4.3.1 Simulation design
We conduct extensive simulations to compare MIRL with alternatives including listwise deletion
least squares regression (LDLS), listwise deletion lasso (LDlasso), multiple imputation with least
squares regression (MILS) combined by Rubin’s Rule, MIRL without stability selection (MIRL−).
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LDLS is the least squares estimation for listwise deleted data after setting the coefficients not
significant at 5% level to be 0; MILS is the least squares estimation for multiply imputed data
setting the combined coefficients not significant at 5% level by Rubin’s rule to be 0; LDlasso is
applying lasso to listwise deleted data with tuning parameter chosen by cross validation; MIRL− is
the multiple imputed random lasso without stability selection, that is, MIRL− uses a hard threshold
and sets the coefficients to be 0 if the absolute values of coefficients are less than 1n where n is the
total sample size.
We simulated 100 data sets of size 400 from the linear model, Y = Xβ + ε, where X is a
n by p matrix of multivariate normal random variables with a pairwise correlation of ρ, and
ε ∼ N (0, In). The first 10 variables have non-zero coefficients as (0.1, 0.2, 0.3, 0.4, 0.5,
−0.1, −0.2, −0.3, −0.4, −0.5), and the others are noise variables. Each data set is separated
into a training set and a testing set with 200 observations each.
We consider 24 scenarios including 2 missing data schemes (MCAR or MAR), 2 missing propor-
tions (50% or 75%), 3 sizes of non-informative variables (p = 25, 50, 100), and 2 pairwise correlations
(ρ = 0.2, 0.6). Specifically, MAR data are generated as follows: covariates X1 and X6 are com-
plete, outcome Y , and covariates X5, X10 are missing with probabilities {1 + exp(−X6 + 2.5)}−1,
{1 + exp(−X1−X6 + 2)}−1 and {1 + exp(X1 + 0.5X6 + 2)}−1, respectively. The other variables are
missing completely at random and the missing probability is set such that overall the proportion
of samples with missing entries on at least one variable is approximately 50% or 75%.
The goal is to evaluate MIRL’s ability in predicting the outcome and its variable selection prop-
erties. The MSPE is used as a measure of prediction ability and Matthews Correlation Coefficient
(MCC) proposed in [Matthews, 1975], defined as following,
MCC =
TP ∗ TN − FP ∗ FN√
(TP + FP ) ∗ (TP + FN) ∗ (TN + FP ) ∗ (TN + FN)
,
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is considered as a measure of overall variable selection performance. Here TP, TN, FP and FN
stand for true positive, true negative, false positive and false negative, respectively.
4.3.2 Simulation results
We present simulation results in Figures 4.2 and 4.3. Firstly, the simulations demonstrate that sta-
bility selection enhances MIRL’s ability in variable selection. MIRL− selects many noise variables,
which may decrease the prediction accuracy. The MCC of MIRL− is much smaller than that of
MIRL in almost all scenarios, which shows that the stability selection step substantially improves
the variable selection ability of MIRL compared to the hard threshold used in the random lasso.
As for the prediction performance, MIRL has slightly larger MSPE than MIRL− for some scenarios
with p = 25, although these differences are within the one-standard error band. As the number of
noise variable increases, MIRL shows more significant advantages. For MCAR 50% and 75% with
pairwise correlation 0.2 and p = 100 scenario, MIRL has significantly smaller MSPE than MIRL−
as presented in Figure 4.2 (a) and (b).
Secondly, the simulations show that the multiple imputation step makes better use of the
available information than listwise deletion. MILS and MIRL are much better than LDLS in both
MSPE and MCC in all scenarios. LDLS is not feasible when p is large and missing proportion is
large because the sample size after listwise deletion is less than the number of variables. LDlasso
outperforms MIRL in the MAR scenario when p = 100, pairwise correlation 0.6 and missing
proportion 50%. In this scenario, there is high correlation between all the informative variables
and noise variables. MIRL selects more noise variables than LDlasso due to their correlation
with important variables. When none or not all of the noise variables are highly correlated with
influential variables, MIRL is expected to show clear advantage. To demonstrate this, we run
additional simulation and present results in Figure 4.4. The three scenarios are all MAR and
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the common missing proportion is 50%, the common pairwise correlation is 0.6. The number of
variables is fixed to be 100 with different numbers of noise variables correlated with informative ones,
0, 40, 90, respectively. We observe that when decreasing the number of noise variables correlated
with informative ones, MCC increases for MIRL and decreases for LDlasso. For example, when
there is no noise variable correlated with informative variables, the MCC of LDlasso is 0.126, which
is 34.1% for MIRL. In the new scenarios, the MSPE of the two methods are not significantly
different.
Thirdly, MILS is MIRL’s closest competitor, and MIRL has comparative advantage over MILS
when the number of variables is large and the correlation between variables are large. MIRL is
significantly better than MILS in both MSPE and MCC when p = 100. For smaller number of
variables, i.e. p = 50, MSPE of MIRL and MILS are not significantly different when pairwise cor-
relation is 0.2, but MIRL has significantly smaller MSPE than MILS when the pairwise correlation
is 0.6. Moreover, the increase of pairwise correlation does not affect the predictive ability of MIRL
much, but it increases MSPE for MILS. For example, in Figure 4.2 (a), for MCAR 50% scenario
with p = 50 and pairwise correlation 0.2, MSPE is 1.208 for MIRL and 1.205 for MILS; when
pairwise correlation is 0.6, MSPE is 1.226 for MIRL and 1.372 for MILS. In addition, for multiple
imputation based methods, MSPE and MCC are not significantly different between two missing
proportions 50% and 75% with the other parameters fixed. Changing the missing data scheme
from MCAR to MAR increases MSPE and decreases MCC; but this does not affect the ranking of
methods.
4.3.3 Simulation summary
Compared with other existing methods, MIRL shows advantages when the data have high propor-
tion of missing and highly correlated influential variables. In addition, in contrast to alternative
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choices, MIRL has the advantage in scaling up to high-dimensional data with large n and p: MIRL
uses a parallel algorithm such that it can be easily distributed in parallel to multiple computing
cores and the results are summarized in the end. Additional simulation results of comparisons with
other existing methods [Johnson et al., 2008; Garcia et al., 2010b] and a scenario where p > n are
provided in Appendix C.1.
4.4 Data Analyses of Project EAT
4.4.1 Main analyses
Here we present analyses of the proposed MIRL and other methods identifying risk and protec-
tive factors for adolescent obesity in Project EAT. Because of the non-monotone and complicated
missing structure, large number of missing variables, diverse types of variables, the application of
[Johnson et al., 2008] and [Garcia et al., 2010b] is difficult. Hence, we compared MIRL with LDLS,
MILS and CW. The analysis of Project EAT data were stratified by gender for comparability with
prior work [Larson et al., 2013]. Our proposed method and competitors were applied to select the
most important of the 62 multi-contextual environmental predictors of BMI z-score among 1307
teenage boys and 1486 teenage girls separately. The estimated coefficient are provided in Table 4.2
for boys and Table 4.3 for girls.
The MSPE are based on 500 replications with training and testing sets of equal sizes. The
MSPEs of LDLS, MILS, CW, and MIRL are 1.2762 (se = 0.0015), 1.2274 (se = 0.0021), 1.2291
(se = 0.0022), and 1.2248 (se = 0.0021) for boys; and 0.8447 (se = 0.0015), 0.8422 (se = 0.0015),
0.8354 (se = 0.0015), and 0.8393 (se = 0.0015) for girls. LDLS yields the largest MSPE, and MILS
is the second largest for both gender. MIRL has smaller MSPE than CW for boys and slightly
larger for girls. The empirical selection probability of MIRL naturally provides a ranking of the
variable importance as shown in Table 4.2. The ranking does not rely on a single tuning parameter
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from one model fit and thus it reduces sensitivity of the model selection to the tuning parameter.
The chosen variable set is therefore more stable than those selected based on a single model. Cross
validation with the one-standard-error rule chose selection probability threshold as 0.9 for both
genders.
MIRL selected 9 variables for boys. In addition to Hispanic, Native American, and Asian boys
having significantly higher BMI z-score, it showed that high social economic status is a protective
factor, higher parental weight status and weight of same gender friends were risk factors. As shown
in the original Project EAT investigation [Neumark-Sztainer et al., 2012; Larson et al., 2013], we
found some reactive factors, such as more unhealthy food at home and higher parental pressure
to eat are associated with lower BMI z-score and higher parental restriction of high-calorie food is
associated with higher BMI z-score.
MIRL also selected 9 variables for girls with 6 overlapping those found for boys and 3 new ones
included more frequent family meals as a protective factor, and lack of neighborhood safety for
day and night and poorer parental role modeling for food choice as risk factors for higher BMI.
The common influential risk factors chosen by MIRL for both genders include social economic
status, parental weight status, parental pressure to eat, parental restriction of high-calorie food,
home unhealthy food availability, and weight status of same gender friend. The estimated effect
directions and magnitudes are similar for these between boys and girls.
MILS identified most of the influential variables that MIRL selected and includes two additional
variables for boys which are age and family meal frequency; and it identified one additional variables
for girls which is encouragement to eat healthy foods. This finding strengthened the the conclusion
that more frequent family meals can be a common protective factor for girls and boys, since it
has high selection probability by MIRL (80.7% for boys and 98.8% for girls) and was selected by
MILS in both genders. Encouragement to eat healthy foods is a reactive factors for girls as it has
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large selection probability by MIRL (89.6%) and also was picked by MILS. Lastly, MIRL was able
to identify weight status of same gender friends for both boys and girls while MILS would have
missed it for girls. Consistent with the simulation results, MILS performed similarly with MIRL
since p = 62 is only a small fraction of the sample size (1307 boys and 1486 girls respectively).
For both genders, CW selected larger sets of variables. For girls it chose the top 19 ranked
by MIRL with the lowest selection probability 79.6%. For boys, the chosen set consists of top 14
variables ranked by MIRL, as well as a few variables with lower selection probabilities, such as
household food insecurity (55%) and black ethnicity group (53.7%). These larger sets of variables
include two possible common influential variables with lower ranks by MIRL than the previous
mentioned variables. Lack of neighborhood safety during night and day was picked for boys by
CW. It is a common risk factor for both gender since CW agrees with MIRL which provided
high selection probability (86.1% for boys and 92.4% for girls), although MILS did not select it.
Park/recreational space area is a common protective factor with is picked by CW for both gender
and has selection probability (79.3% for boys and 79.6% for girls).
LDLS (based on n = 252 boys and n = 271 girls with complete entries) identified fewer variables
than other methods. It identified 3 common variables for both genders, including parental pressure
to eat, parental weight status and weight status of same sex friends which are also selected by
MIRL. It missed the other variables chosen by MIRL, MILS and CW, and selected parental role
modeling of food choices for boys, which is not picked by any other method and with low selection
probability from MIRL (31.1%). Parental restriction of high-calorie food was chosen as a risk factor
for girls by LDLS as in other methods. These analyses suggested that loss of information due to
listwise deletion reduced the power to identify some potentially important variables.
The magnitudes of the coefficients obtained directly from MIRL, MILS and CW were found
to be different for some variables. One reason is that MIRL’s coefficients are averaged across
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bootstrapped samples including zero for the variables either not sampled in step 3 or shrunk to
0 when applying lasso regression. Thus although we expect these coefficients to be consistent
asymptotically, for finite samples, the shrinkage effect for the magnitude of covariates might be
evident. The same phenomenon was observed for random lasso [Wang et al., 2011a]. One way to
mitigate the difference is to refit the model using the selected variables as suggested in CW. We
present the refitted coefficients in Table 2 and 3 for MIRL, MILS and LDLS, where we can see
that the coefficients for the chosen variables have the same signs, and MIRL and MILS coefficient
estimates are similar since they chose similar sets of variables. Because the LDLS chose many less
variables, the difference of the magnitudes for the refitted variables is large due to collinearity of
covariates.
4.4.2 Subgroup analyses
Next, we compare the methods in a targeted subsample previously identified as at high risk of
being overweight [Larson et al., 2013]. One strength of Project EAT is its ethnically diverse sample
including: 19% non-Hispanic White, 29% Black, 17% Hispanic, 20% Asian, 4% Native Americans,
and 11% Mixed/Other as well as a large proportion of low-income adolescents. Hence, in addition
to identifying risk and protective factors for the whole population, it is feasible to identify risk
factors among specific at-risk sub-population so that interventions can be targeted. Asian teenage
boys in Minneapolis/St. Paul were found to have the largest secular increases in overweight status
going from 30% overweight in 1999 to 50% in 2010 [Neumark-Sztainer et al., 2012]. Thus it is of
interest to consider specifically risk and protective factors within the sub-sample of n = 99 low
social economic status (SES) Asian boys.
In this subgroup, there were only 20 subjects with complete data which is less than the number
of predictors. We excluded SES and race, which are degenerated in this analysis. We compared
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MIRL, MILS, and CW where only MIRL identified an important predictor. For MIRL, cross
validation chose 90% as the threshold, and parental weight status was identified with selection
probability 91.2%. All other variables have selection probability lower than 80%. Parental weight
status is a strong predictor from a behavioral genetics perspective [Kral and Faith, 2009] and it is
also picked in the larger sample analysis by all available methods. For MILS, the p-value of parental
weight status is 0.5188. Table C.10 in the appendix presents coefficients from MIRL and MILS for
the top 10 variables with highest ranking in MIRL. The analysis for this subgroup demonstrates
MIRL’s advantages when the variable number p is relatively large compared to the sample size
n: MIRL detected some influential variables while MILS and CW detected none. These results
are consistent with our simulation results where MIRL shows greater comparative advantages over
MILS and other methods in the cases with larger p and smaller n.
4.5 Conclusion and Discussion
In conclusion, we recommend MIRL for the analysis of Project EAT data. MIRL selected 9 variables
for boys and girls, respectively. High weight status of parents and same gender friends are common
risk factors. High social economical status is a common protective factor. Parental pressure to eat,
parental restriction of high- calorie food and home unhealthy food availability are common reactive
factors. In addition, Asian, Hispanic and Native American ethnicity groups are associated with
higher BMI in boys. For girls, neighborhood unsafeness, poor parental role modeling of food choice
are risk factors; and more frequent family meal is a protective factor.
MIRL is proposed as a procedure to address the missing data issue in variable selection for
high-dimensional data through multiple imputation. When the number of variables with missing
is large, alternative methods to adjust for missingness (e.g., likelihood-based methods through EM
algorithm or inverse probability weighting) become difficult or infeasible. Our simulation results
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show that for low-dimensional case (e.g., p = 25, n = 200), the least squares regression for multiply
imputed data (MILS) can outperform more sophisticated lasso-based variable selection methods.
However, when the number of predictor variables increases, the advantage of lasso-based methods
can be substantial. Regarding the influence of missing, the efficiency loss in terms of MSPE for
a complete data analysis is considerable even when missing proportion is moderate (e.g., 50%
complete data left after listwise deletion).
MIRL is especially suitable for cases where the informative variables are likely to be correlated
and it performs adequately when the noise variables are correlated with the informative ones. In
this case, the bootstrap samples and random draw of variables according to the importance measure
enable variables highly correlated with the outcome to have high selection probability and other
noise variables to have low selection probability despite their correlation with the informative ones.
Another advantage of MIRL lies in its flexibility in dealing with many missing data structures and
variable selection techniques. In the imputation step, other imputation approaches such as MCMC
can replace MICE. In the second step where penalized regression for each bootstrap sample is
performed, other methods such as regression with SCAD penalty [Fan and Li, 2001] and elastic
net penalty [Zou and Hastie, 2005] can be used instead of lasso. In addition, although we focus on
MIRL using linear model for continuous outcomes, it can be easily extended to generalized linear
models for categorical outcomes, Cox regression model for censored outcomes and mixed effects
models for longitudinal outcomes.
One extension of MIRL is to consider mixed effects models to allow random effects (e.g., school-
specific random effects in Project EAT). [Groll and Tutz, 2014] proposed variable selection method
to introduce L1 penalty in mixed effects model. A possible solution is to conduct variable selection
with random effects for each bootstrapped samples of imputed data, and combine coefficients from
imputed data sets by taking the average. Further investigations are needed to draw inference for
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combining the multiply imputed correlated data or bootstrapped sample.
Lastly, since MIRL combines random lasso [Wang et al., 2011a] and stability selection [Mein-
shausen and Buhlmann, 2010] to analyze multiply imputed data, it is of interest to consider whether
theorems developed for stability selection can be applied. Since the imputation is performed for
the covariates in the design matrix, the random errors are independent when treating design ma-
trix X as fixed in a regression problem. It is conjectured that an adapted version of Theorem 2
in [Meinshausen and Buhlmann, 2010] can be used to provide some insights for variable selection
consistency of MIRL when the imputed design matrices satisfy sparse eigenvalue Assumption 1 in
[Meinshausen and Buhlmann, 2010]. However, rigorous theoretical investigation of MIRL is beyond
the scope of this work.
CHAPTER 4. MULTIPLE IMPUTED RANDOMIZED LASSO 91
Figure 4.1: A Flowchart of the MIRL Algorithm as Described in Section 3
Input: A sample of n observations with p predictor variables with possible
missing
Step 1. Impute the sample m times and standardize all variables
Step 2. For each imputed data set, generate B bootstrap samples
a) Compute lasso-OLS coefficients for each bootstrapped sample
b) Compute the importance measure for each of the p variables as the ab-
solute value of the simple average of the m×B coefficients
Step 3.
a) For each m × B dataset, randomly select p/2 variables with probability
proportional to importance measures; compute lasso-OLS coefficients for
p/2 variables and set the rest to be 0
b) Average m×B coefficients to get initial MIRL estimates
Step 4.
Compute empirical selection probabilities and chose probability threshold
by cross-validation, under which the MIRL estimates are set to be zero
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Table 4.1: Most Frequent (>=1%) Missing Patterns of Some Important Variables in Project EAT
Data (“X” indicates non-missing and “.” indicates missing)
Variables % Missing Missing Patterns
Parental pressure to eat 18 X X . . X X X X X
Parental restriction of high-calorie food 18 X X . . X X X X .
Asian 0 X X X X X X X X X
Parental weight status 21 X X . . . . X X X
Home unhealthy food availability 0 X X X X X X X X X
Hispanic 0 X X X X X X X X X
Social economical status 5 X X X X X X . . X
Weight status male friends 36 X . X . X . X . X
Native american 0 X X X X X X X X X
Missing Pattern Percentage (%) 48 26 9 5 2 2 1 1 1
∗: Marginal missing proportion for each variable.
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Table 4.2: Comparison of MIRL with MILS, LDLS and CW for Project EAT Data (Boys)
Variables MIRL MILS LDLS CW
refit raw est. prob.† refit raw est. p-value refit raw est. p-value
Parental pressure to eat -0.2664 -0.1779 1.0000 -0.2604 -0.2676 < 0.0001 -0.1830 -0.1108 < 0.0001 -0.2633
Parental restriction of
high-calorie food
0.2166 0.2301 0.9980 0.2044 0.2001 < 0.0001 0 0.0303 0.0613 0.1804
Asian 0.1765 0.0843 0.9970 0.1727 0.1903 0.0001 0 0.2753 0.3189 0.1713
Parental weight status 0.2117 0.1662 0.9960 0.2044 0.1925 < 0.0001 0.2175 0.0269 0.0341 0.1922
Home unhealthy food
availability
-0.1058 -0.1313 0.9610 -0.1017 -0.0875 0.0115 0 -0.0229 0.4993 -0.0981
Hispanic 0.1361 0.0118 0.9595 0.1408 0.1312 0.0033 0 -0.1621 0.5623 0.1225
Social economical status -0.1090 -0.0787 0.9580 -0.1032 -0.0928 0.0187 0 -0.0200 0.7636 -0.0784
Weight status male
friends
0.0861 0.0985 0.9470 0.0861 0.0844 0.0258 0.1116 0.5116 0.0106 0.0862
Native american 0.0911 0.0383 0.9180 0.0825 0.1021 0.0092 0 0.5176 0.2762 0.0813
Neighborhood unsafeness 0 0.0567 0.8605 0 0.0559 0.0968 0 -0.0211 0.9227 0.0690
Age 0 -0.0773 0.8230 -0.0774 -0.1281 0.0147 0 -0.0448 0.5384 -0.0753
Presence of convenience
store in 800 m
0 -0.0539 0.8080 0 -0.1668 0.0503 0 -0.6854 0.1605 -0.0769
Family meal frequency 0 -0.0143 0.8065 -0.0589 -0.0701 0.0411 0 0.0117 0.7446 -0.0559
Park/recreation space (%
of area)
0 -0.0373 0.7925 0 -0.0518 0.1471 0 -0.3328 0.0523 -0.0458
Encouragement to eat
healthy foods
0 0.0144 0.7715 0 0.0721 0.0583 0 0.1106 0.2884 0
Presence of convenience
store in 1200 m
0 0.0116 0.7640 0 0.0578 0.1062 0 -0.1481 0.6209 0.0563
Number of male friends in
sample
0 0.0161 0.7310 0 0.0497 0.2322 0 0.1559 0.1703 0.0407
Sedentary behavior fe-
male friends
0 0.0043 0.6460 0 -0.0337 0.3895 0 0.0025 0.5103 0
Neighborhood unsafeness
during the night
0 -0.0167 0.6430 0 -0.0459 0.1724 0 -0.2547 0.1777 0
Moderate-to-vigorous PA
female friends
0 -0.0087 0.6360 0 -0.0196 0.6340 0 -0.0133 0.4987 -0.0459
Parental time spent
watching TV with
0 0.0305 0.6315 0 0.0352 0.3346 0 -0.0121 0.7611 0
Healthy food served at
family meals
0 -0.0013 0.6045 0 -0.0447 0.2206 0 -0.0141 0.6569 0
Fast-food frequency male
friends
0 0.0101 0.5815 0 0.0696 0.1346 0 0.0447 0.1848 0
Household food insecurity 0 0.0405 0.5500 0 0.0207 0.5901 0 0.2160 0.2115 0.0349
Limited variety of fruits
and veges
0 -0.0425 0.5435 0 -0.0598 0.1744 0 -0.1286 0.3444 0
Black 0 -0.0210 0.5370 0 -0.0069 0.8864 0 -0.1754 0.5081 -0.0071
Weight status female
friends
0 0.0167 0.5200 0 0.0309 0.4901 0 0.1742 0.3890 0
Friends’ support for PA 0 -0.0069 0.5095 0 -0.0265 0.4385 0 -0.0050 0.9018 0
Friends’ attitudes of eat-
ing healthy foods
0 0.0191 0.5080 0 0.0461 0.1860 0 0.0119 0.8967 0
Number of female friends
in sample
0.0065 0.4645 0 0.0326 0.4601 0 0.0729 0.5432 0
. . .
Parental role modeling of
food choices
0 0.0015 0.3110 0 -0.0225 0.5766 -0.0392 -0.0542 0.0487 0
. . .
†
Selection probability provided by MIRL.
Note: Top 30 (based on MIRL) of the 62 predictors are shown plus any other predictors selected by other methods.
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Table 4.3: Comparison of MIRL with MILS, LDLS and CW for Project EAT Data (Girls)
Variables MIRL MILS LDLS CW
refit raw est. prob. † refit raw est. p-value refit raw est. p-value
Social Economic Status -0.1037 -0.1206 1.0000 -0.1147 -0.0900 0.0022 0 -0.0700 0.1790 -0.0889
Parental pressure to eat -0.2079 -0.2528 1.0000 -0.2068 -0.2150 <0.0001 -0.1830 -0.1023 < 0.0001 -0.2065
Parental restriction of
high-calorie food
0.2191 0.2679 1.0000 0.2165 0.2317 <0.0001 0.2313 0.0443 0.0004 0.2160
Parental weight status 0.1855 0.1646 1.0000 0.1987 0.1714 <0.0001 0.1994 0.0296 0.0065 0.1811
Home unhealthy food
availability
-0.1005 -0.1001 0.9960 -0.0888 -0.1060 0.0001 0 -0.0071 0.7479 -0.1007
Family meal frequency -0.0776 -0.0814 0.9880 -0.0882 -0.0843 0.0011 0 -0.0364 0.1480 -0.0802
Weight status female
friends
0.0735 0.0183 0.9360 0 0.0534 0.1434 0.0799 0.3500 0.0282 0.0540
Neighborhood unsafeness
during the night and day
0.0557 0.0470 0.9240 0.0518 0.0642 0.0161 0 0.2550 0.0922 0.0553
Parental role modeling of
food choices
-0.0410 -0.0211 0.9200 -0.0742 -0.0659 0.0311 0 -0.0105 0.6068 -0.0720
Hispanic 0 0.0338 0.8960 0 0.0478 0.1748 0 0.2774 0.2258 0.0497
Encouragement to eat
healthy foods
0 0.0043 0.8960 0.0787 0.0822 0.0066 0 0.0964 0.2165 0.0818
Schools commitment to
promoting PA
0 -0.0243 0.8960 0 -0.0299 0.7120 0 -0.1069 0.6960 -0.0605
Asian 0 -0.0458 0.8680 0 -0.0482 0.2300 0 0.1633 0.4959 -0.0507
Parental fast food intake 0 0.0280 0.8560 0 0.0414 0.1976 0 0.0242 0.6410 0.0372
Presence of convenience
store in 1200 m
0 0.0306 0.8560 0 0.0520 0.0592 0 0.2049 0.3285 0.0314
Moderate-to-vigorous PA
female friends
0 -0.0327 0.8440 0 -0.0522 0.0683 0 -0.0236 0.1632 -0.0383
Parental time spent sup-
porting PA
0 0.0195 0.8080 0 0.0599 0.1410 0 0.0130 0.6853 0.0525
Weight status male
friends
0 0.0276 0.8080 0 0.0368 0.2137 0 0.1555 0.3021 0.0447
Park/recreation space (%
of area)
0 -0.0516 0.7960 0 -0.0360 0.1927 0 -0.0467 0.7186 -0.0356
Schools commitment to
promoting healthy eating
0 -0.0143 0.7480 0 -0.1173 0.1330 0 0.0784 0.7962 0
TV during dinner 0 -0.0015 0.6760 0 0.0224 0.3769 0 0.0005 0.9931 0
Limited variety of avail-
able fruits and vegetables
0 -0.0129 0.6480 0 -0.0375 0.2462 0 0.0589 0.5608 0
Students allowed to drink
during class
0 0.0182 0.6440 0 0.0244 0.7891 0 -0.1200 0.8501 0
Indoor campus PA facili-
ties
0 -0.0042 0.6240 0 -0.0434 0.4623 0 -0.0819 0.4320 0
Home healthy food avail-
ability
0 -0.0141 0.6000 0 -0.0137 0.6533 0 -0.0299 0.2173 0
Distance to nearest
gym/fitness center (m)
0 -0.0055 0.5880 0 0.0288 0.2899 0 0.0870 0.4931 0
Poor quality of fruits or
vegetables
0 -0.0205 0.5520 0 -0.0237 0.4762 0 -0.0704 0.5297 0
Age 0 -0.0009 0.4520 0 -0.0516 0.2040 0 -0.0112 0.8407 0
Density of total crime in-
cidents
0 0.0107 0.4440 0 0.0083 0.7629 0 0.0634 0.6367 0
Native American 0 0.0068 0.4240 0 0.0207 0.4669 0 -0.0210 0.9548 0
. . .
†
Selection probability provided by MIRL.
Note: Top 30 (based on MIRL) of the 62 predictors are shown.

















































































(d) MAR with 75% Incomplete Entries
Figure 4.2: Prediction Performance Comparisons of MIRL with Other Methods under 4 Missing
Schemes with Varying Number of Variables and 2 Pairwise Correlations†
†There are some missing or off-chart points for LDLS because when the number of variables is large and missing proportion is
big, LDLS fails to give a reasonable estimator. Tables of exact numbers are omitted due to the page number limit, these tables
can be provided upon request.





















































































(d) MAR with 75% Incomplete Entries
Figure 4.3: Variable Selection Performance Comparisons of MIRL with Other Methods under 4
Missing Schemes with Varying Number of Variables and 2 Pairwise Correlations†
†Tables of exact numbers are omitted due to the page number limit, they can be provided upon request.
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(a) Performance of Prediction in MSPE (b) Performance of Variable Selection in MCC
Figure 4.4: Performance Comparison for Varying Number of Correlated Variables for a MAR
Scenario with 50% Incomplete Entries, p = 100 and Pairwise Correlation 0.6.
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Chapter 5
Future Works
One direct extension for AMOL in Chapter 2 is to deal with high dimensional data and to do
variable selection. AMOL is a general framework that transfers the problem of maximizing the
value function into a weighted classification problem. SVM naturally incorporates L2 penalty for the
coefficients in the estimated decision function so that it can solve problems with high dimensional
feature variables. To do variable selection, one can implement SVM with lasso, SCAD, or elastic-net
penalties to yield sparse coefficients. In addition, the hinge loss of SVM can be replaced by other
loss functions corresponding to other classification methods such as logistic regression, classification
trees and neural networks. In addition, the appendix of a related working paper in [Luedtke and
van der Laan, 2014] described the idea of double robust estimation, but without explicit SVM
implementation or the consideration of convergence rates of the learning algorithm. It would be
interesting to further explore how to combine the advantages of AMOL and their super learning for
improving the estimation of personalized treatment regimes. Super learning is a way to ensemble
different estimated decision functions, and it guarantees that, in a SMART, the super-learner will
be asymptotically equivalent with the estimator selected by the oracle selector. It is of interests to
derive inference for the estimated optimal decision function from AMOL, and the inference of the
ensembled estimator with estimators from various lose functions and kernels for AMOL and other
methods.
It is an important question to address the uncertainty of this estimated rule from AMOL and
be able to inform the patients and clinicians the benefits of each individual patient to follow the
optimal rule. One way is to use predictive modeling approaches (Q-learning) to estimate the
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contrast function for each individual patient , or the probability of patient reponse by adopting
such estimated optimal rule and the predicted classification label or the decision function could
be included as a predictor in the regression models of Q-learning. Whether this will enhance the
prediction of the contrast function is an open question.
On the other hand, it is also interesting to extend the current framework to deal with the
combinations of various outcomes and other types of input variables. Multiple endpoints may be
a better measurement than one-dimensional continuous outcome to represent the information for
alleviation of symptoms [Teixeira-Pinto et al., 2009], For example, one may need to consider the
increased quality of life and functioning, time to response, and reduction of side effects. It is worth
exploring machine learning methods to deal with multi-dimensional responses or multi-dimensional
value functions. Another extension is to allow AMOL to incorporate imaging data as the feature
variables. Such imaging data includes fMRI, MRI, EEG data that may come from psychiatry,
neurology or cardiovascular studies. It worth exploring the merge of methods for functional analysis,
computer vision or other machine learning techniques with our weighted classification approach to
make personalized diagnosis or treatment decisions. It is also of interest to extend AMOL to handle
more than two treatment groups through multi-category classification. Lastly, the frequency of
patients switching their treatment throughout the dynamic treatment process is a factor we can
extend AMOL to tailor for the specific need and preference in real clinical applications.
The method we proposed in Chapter 3 considers maximizing diagnostic performance of a clinical
test at the diagnostic stage, which is the first step of the clinical care continuum [Zapka et al.,
2003]. When information at other stages are available (i.e., treatment received) and maximizing
long term morbidity or minimizing mortality is the ultimate goal, it is conceivable that a multiple
stage decision rule which dynamically determines diagnostic choice and treatment choice can be
constructed. Our method can be extended to handle multi-stage personalized rules by a backward
induction procedure similar to that used for estimating optimal multi-stage personalized treatment
rules [Zhao et al., 2014]. Another interesting extension maybe to consider comparing two screening
strategies with different timing or frequency, and thus extends the current optimization method
from choosing between two modalities to choosing on a continuous scale (timing of screening).
Lastly, the proposed methods are illustrated through retrospective case-control diagnostic studies.
For prospectively studies, it may be more appropriate to assess positive predictive values (PPV)
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and negative predictive values (NPV). An extension towards this direction would also be of interest.
Lastly, the method MIRL in Chapter 5 can be integrated into Q-learning, as a way to con-
duct variable selection and prediction when there is missing entries in the feature variables. It is
interesting to pose the similar question to AMOL, i.e. how to deal with missing data problem in
the weighted classification approaches for personalized medical decision making. For complicated
missing data structure with high dimensional feature variables, multiple imputation is a flexible
way to handle the problem of missing. It is interesting to explore how to do variable selection with
penalized SVM for multiple imputed data set.
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Appendix A
Appendices for Chapter 2
A.1 Performance of AMOL for Single-Stage Randomized Trials
Here we demonstrate through simulation studies the benefits of AMOL compared to OWL for single
stage randomized trials. We generated rewards from a linear model, R = 2X3−X4 +A(X1−X2)+
N (0, 1), and generated covariates from a multivariate normal distribution with pairwise correlation
0.2 and variance 1. The number of covariates is 10 (including 4 informative variables and 6 noise




We compared three approaches. The first approach is the original OWL [Zhao et al., 2012],
where the weights are shifted to be positive by using R−min(R). The second approach is a modified
OWL utilizing our proposed algorithm to deal with the negative weights (referred as Modified in
Figure A.1) by using |R|/P (A|H) as the weights and sign(R)A as the class labels to estimate
the optimal rule. The third approach is AMOL in a single stage trial, where the variability of
rewards is further reduced by taking out the main effects of the feature variables, that is, by using
|R− s(H)|/P (A|H) as the weights and sign(R− s(H))A as the class labels.
Results for four sample sizes (50, 100, 200, 400) are presented in Table A.1 and Figure A.1. We
can see that using proposed algorithm for dealing with negative weights, the Modified OWL has
much larger means and smaller variances of the value function than OWL for all sample sizes.
After taking residuals to further reduce the variability of the rewards, the single stage AMOL is
the best among three, in terms of the largest mean value function and smallest variability. The
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Table A.1: Mean and median of empirical value function for 3 simulation scenarios evaluated on
independent testing data.
Simulation setting S1 (optimal value 1.009)
n OWL Modified AMOL
Mean (Std) Median Mean (Std) Median Mean (Std) Median
50 0.183(0.274) 0.139 0.565(0.250) 0.639 0.779(0.128) 0.811
100 0.290(0.286) 0.306 0.777(0.134) 0.800 0.912(0.047) 0.922
200 0.404(0.294) 0.468 0.889(0.055) 0.900 0.960(0.022) 0.964
400 0.549(0.291) 0.634 0.939(0.030) 0.944 0.981(0.011) 0.983
value function approaches the optimal as the sample size increases, where it reaches a median of
0.983 when sample size is 400.
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Figure A.1: Performance of single-stage AMOL, optimal value 1.009
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A.2 Simulation Studies for Two-stage Randomized Trials
In the first scenario (Setting S1) for two-stage studies, the rewards (outcomes R) are generated
based on regression models. There are p = 20 feature variables simulated from a multivariate
normal distribution, where the first ten variables X1 to X10 have a pairwise correlation of 0.2, and
the rest 10 variables are uncorrelated. The outcome model is:
R1 = X1 ∗A1 +N (0, 1); R2 = (R1 +X22 +X23 − 0.8) ∗A2 +N (0, 1).
The randomization probabilities at both stages depend on the feature variables through:
P (A1 = 1|H1) =
1
1 + exp(−0.5X1)




In the second scenario (Setting S2), the rewards (outcomes) are generated based on a pattern
mixture model using a latent variable L similar to the four-stage setting in Section 4 but with four
latent groups instead of ten. For subjects in each group indicated by L, their optimal treatments
V ∗ = (A∗1, A
∗
2) are generated from (1, 1), (1,−1), (−1,−1), or (−1, 1). There are 30 feature variables
X simulated from a normal distribution, where the first 10 variables are informative and the rest
are non-informative. We generate 10 centroids of the informative variables from another normal
distribution with mean 0 and standard deviation of 5, and thus the informative variables contain
information to distinguish the latent groups L (different centroids). The rewards are generated
as: R1 = 0, R2 = A
TV ∗ + N(0, 1). Therefore the total expected optimal rewards is 2 when the
treatment assignments in both stages coincide with the optimal treatments for a given subject in a
group. The mean suboptimal rewards are 0 or −2 when one or neither stage’s treatment is optimal,
respectively.
Details on the implementation of Q-learning, OWL and AMOL are described in Section 4. The
simulation results are given in Table C.1 and Figures A.2 and A.3. The conclusions are similar
to the four-stage scenario reported in the main texts. We observe much improved performance of
AMOL compared to OWL (higher value function and lower variability). For example, with the
sample size of 400, the mean value was 2.502 for AMOL and 1.289 for OWL in scenario 1. In
addition, AMOL outperforms Q-learning with small sample size of n = 50. Since in scenario 1, the
reward is generated from a regression model, Q-learning quickly achieves near theoretical optimal
value with increased sample size, while AMOL improves steadily and catches up with Q-learning.
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Table A.2: Mean and median of empirical value function for 3 simulation scenarios evaluated on
independent testing data.
Simulation setting S1 (optimal value 3.1)
n Q-learning OWL AMOL
Mean (Std) Median Mean (Std) Median Mean (Std) Median
50 1.58(0.964) 0.836 0.658(0.776) 0.661 1.607(0.481) 1.663
100 2.404(0.797) 2.832 0.845(0.746) 0.931 1.945(0.379) 2.029
200 2.803(0.239) 2.838 1.029(0.715) 1.106 2.246(0.277) 2.3
400 2.833(0.092) 2.838 1.289(0.698) 1.241 2.502(0.14) 2.526
Simulation setting S2 (optimal value 2.0)
n Q-learning Olearning AMOL
Mean (Std) Median Mean (Std) Median Mean (Std) Median
50 0.112(0.254) 0.006 0.404(0.386) 0.378 1.19(0.364) 1.204
100 0.309(0.39) 0.028 0.628(0.371) 0.605 1.528(0.281) 1.563
200 0.59(0.365) 0.694 0.853(0.351) 0.826 1.731(0.201) 1.77
400 0.81(0.239) 0.846 1.144(0.31) 1.143 1.834(0.157) 1.882
For scenario 2, AMOL performs much superior than Q-learning and OWL with a near two-fold
increase in value function. This is due to that Q-learning regression model is highly misspecified in
scenario 2.
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Figure A.2: Setting S1: 2 stages, optimal value 3.1
Figure A.3: Setting S2: 2 stages, optimal value 2
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A.3 Application to STAR*D Study
Our second real data application is to the Sequenced Treatment Alternatives to Relieve Depression
(STAR*D) trial. The STAR*D was a phase-IV multi-site, prospective, multi-stage randomized
clinical trial to compare various treatment regimes for patients with non-psychotic major depressive
disorder [Rush et al., 2004]. The aim of the STAR*D was to find the best subsequent treatment for
subjects who failed to achieve adequate response to an initial antidepressant treatment (citalopram).
The primary outcome was measured by the Quick Inventory of Depressive Symptomatology (QIDS)
score ranging from 0 to 26 in the sample. Participants with a total clinician-rated QIDS score
under 5 were considered as having a clinical meaningful response to the treatment and therefore in
remission. Remitted patients were not eligible for any future treatments and entered a follow up
phase.
All participants in the STAR*D trial were initially treated with citalopram (CIT), the Level
1 treatment, for a minimum of 8 weeks. Participants who either did not have an adequate re-
sponse or could not tolerate citalopram entered Level 2 of the trial, which was the first stage of the
randomization (stage 1 randomization). At this stage, participants were randomized to receive ei-
ther a) treatments involving selective serotonin reuptake inhibitors (SSRI): CIT+buspirone (BUS),
CIT+bupropion (BUP), CIT+cognitive therapy (CT) and sertraline (SER); or b) non-SSRI treat-
ments: CT, BUP and venlafaxine (VEN). Participants who achieved remission at the end of Level
2 treatment entered a follow up study, and participants who did not were eligible to be enrolled in
the next stage. For participants without a satisfactory response to their Level 2 treatment and who
were switched to or augmented by cognitive therapy, they entered level 2A, and were randomly
assigned to switch to one of two antidepressant medications (venlafaxineXR or bupropion SR). In
the second stage of the randomized trial (stage 2 randomization), participants were randomized
among several Level 3 treatments: a) SSRI including SER + lithium (Li) and thyroid hormone
(THY); or b) non-SSRI including mirtazapine (MIRT), nortriptyline (NTP), BUP+Li or THY and
VEN+Li or THY.
To compare performance of various methods on estimating the optimal DTR, we combined
treatment assignments into two categories (treatments involving an SSRI versus treatments without
SSRI) as done in [Chakraborty and Moodie, 2013]. For the first stage, the baseline QIDS score,
the slope for level 1, participant preference and QIDS at the beginning of stage 1 randomization
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(Level 2 treatment) were included as tailoring variables [Pineau et al., 2007]. For the second stage,
intermediate outcomes of QIDS at week 9 during stage 1, QIDS change score in stage 1, starting
QIDS score at stage 2 randomization (Level 3 treatment), participant preference at stage 2, and
treatment assignment history at stage 1 were included as tailoring variables. There were 1381
participants with complete feature variables for the first stage analysis, among whom 516 achieved
remission at the end of the first stage. Among 865 non-remitted participants, 364 of them had
entered the second stage and have complete information on the feature variables and outcomes.
Missingness was adjusted by inverse probability weighting. Since a smaller QIDS is desirable,
negative QIDS score was defined as the reward in our algorithm to maximize the value function.
For participants in remission at the end of the first stage, their reward was negative QIDS at stage 1;
for those who had not achieved remission after stage 1, their reward was the negative of the average
of QIDS scores at both stages [Chakraborty and Moodie, 2013]. Comparison of the methods were
based on 500 repetitions of 2-fold cross validation (CV).
The first stage randomization probability π1 was estimated by the frequency of SSRI and non-
SSRI given patient preference at stage 1, which took values in (-1, 0, 1) for the 1381 patients. The
second stage randomization probability π2 was computed as the frequency of treatment SSRI and
non-SSRI given patient preference at stage 2. There were 364 patients completed stage 2 data and
analyzed for stage 2. And there were 501 non-remissed patients dropped out after the first stage.
We dealt with this missing problem with inverse probability weighting for O-learning for the first
stage, where the drop out probability mis2 was estimated by the frequency of complete data for
those non-remissed.
LASSO penalty was used in both Q-learning and the regression steps of AMOL. The remissed
patients were treated as having received their optimal treatments at the second stage, and thus to
estimate the optimal rule for the second stage all three methods used the non-remissed patients.
For the first stage, Q-learning used all patients with complete data at this stage and the outcomes
for the remissed patients were the first stage outcomes, while the outcomes for the non-remissed
ones were the average of their first stage outcomes and predicted second stage outcomes. For O-
learning, the outcome for the remissed patients was the first stage outcome weighted by π1, while
the outcome for the non-remissed patients is the average of first and second stage outcome weighted
by π1 ∗ π2 ∗mis2.Similarly, for AMOL the remissed subjects’ first stage outcomes were weighted
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Figure A.4: Mean and standard error of value function (depression symptom score QIDS) based
on 500 2-fold CV for STAR*D data (lower score desirable)
by π1, and for non-remissed patients, AMOL pseudo outcomes were weighted by π1 ∗mis2. The
empirical value function was computed by inverse probability weighting as the definition of value
function in Section 2.1, where Dk’s were optimal rules estimated by each method. We also handled
the missingness of the non-remissed patients by inverse probability weighting.
Q-learning, O-learning, and AMOL were compared in Figure A.4. The mean baseline clinician-
rated QIDS score in the sample was 16.71 and the mean QIDS at the start of stage 1 randomization
was 12.37. The average QIDS score for the optimal DTR obtained by AMOL after two stages was
6.92 (sd = 4.60) points on the testing sample, which outperformed Q-learning (8.20, sd = 2.48) and
O-learning (11.69, sd = 0.99). Since QIDS score below 7.0 was considered as in remission, AMOL
estimated optimal rule was estimated to lead to a clinically meaningful benefit in this analysis.
AMOL-estimated rule also outperformed the one-size-fits-all rules (e.g., all subjects receive SSRI
in both stages, all subjects received SSRI in the first stage and non-SSRI in the second and so on).
The best among the four potential one-size-fits-all treatment strategies achieved an average of 7.20
points in QIDS (assigning SSRI for first stage and non-SSRI for the second stage), and the worst
achieved 8.73 points (SSRI for both stages).
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Figure A.5: Normalized coefficients of the stage 1 tailoring variables (left panel) and stage 2 tailoring
variables (right panel) obtained by AMOL
Q-learning with LASSO penalty did not select any tailoring variables, therefore there were
no personalized treatment rules as estimated by Q-learning. The estimated value function of Q-
learning was about the average of all one-fits-all rule. In most repetitions of the cross-validation,
Q-learning did not select any treatment by feature variable interaction terms, and thus the value
function was estimated similar to random assignment of treatments.
We present normalized effects for the optimal DTR obtained by AMOL in Figure A.5. We
normalized the effect of each tailoring variable through dividing by the L2 norm of all coefficients
of the decision rules. The baseline variables with strongest effects were baseline QIDS score, rate
of change of QIDS in the previous period, and patient preference. The strongest second stage
tailoring variables were intermediate outcome after stage 1 treatment, starting QIDS at stage 1,
and patient preference for the second stage treatment. As a note, in this real data example, the
proposed augmentation for AMOL based on weighted least squares m̂kj does not give an advantage
over augmentation using Q-function. The above results for AMOL are obtained with m̂kj imputed
by Q-function with lasso penalty.
In conclusion, the STAR*D example demonstrates that AMOL outperforms the best one-size-
fits-all rule and the other existing methods in maximizing clinical benefits, and the example also
yields some insights on AMOL’s ability on combining tailoring variables to perform deep tailoring
and to form new treatment rules.
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Appendix B
Appendices for Chapter 3
B.1 Simulations Under Unpaired Design
We simulated covariates Xi, disease status Di and screening scores YAi and YBi under a similar
procedure as the paired design in section 4.1. In addition, we created random variable M = 1 when
modality A is observed and M = −1 when modality B is observed. We implemented the unpaired
algorithm with a triangular kernel (1 − ‖x1 − x2‖/an)+. We simulated three scenarios where the
modalities are generated following equation 1 and 2. Case 1 and 2 has p = 6 dichotomized variables
Xi’s. Here we consider equal weights ω = 0.5. And the bandwidth of kernel function is chosen to
be an = 1.5 in both cases, thus each sample is matched with samples at most 1 predictor Xi is
not mismatched. The number of observations n is 64 in case 1 and 128 in case 2. So that there
is approximately 441 and 889 paires considered respectively. Simulation case 3 of the unpaired
design considers the same modalities with continuous covariates, where X is generated from a
multivariate normal distribution with p = 10. And sample size is n = 100. We are considering
the same two cases for the covariance matrix of error terms for YA and YB, ω = 0.5, and an = 1
(chosen by cross validation). The results are reported in table B.1 and Figure B.1. The methods
perform similarly for independent modality measurements and correlated modality measurements.
Comparing case 1 and 2, we see the increase of sample size from 64 to 128 greatly improves the
performance of proposed method. In these settings, wSVM2 performs better than wSVM1. For
example, in case 2, it improves the empirical AUC by 13%, and we see a large gap between its
average ROC curve compared to other three methods. Thus weighting by the magnitude of the
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difference in two modality screening scores makes a difference in this simulation scenario. Case 3
is a more difficult case, where there are more noise variables, and the covariates are continuous
instead of categorical. In this setting, the bandwidth of the kernel function was chosen to be a = 1
from a grid of {0.75, 0.9, 1}. We see wSVM1 and wSVM2 both improve the empirical AUC over
“one-size-fits-all” rules by approximately 1% and 4%, respectively.
Table B.1: Mean (SD) for Empirical AUC for Unpaired Design Simulation with independent and
correlated modality measurements
modality A modality B wSVM1 wSVM2
Independent Correlated Independent Correlated
Case 1 0.739 0.752 0.751(0.026) 0.753(0.027) 0.771(0.05) 0.767(0.047)
Case 2 0.739 0.752 0.765(0.053) 0.761(0.039) 0.834(0.083) 0.838(0.083)
Case 3 0.742 0.745 0.748(0.017) 0.750(0.021) 0.767(0.037) 0.775(0.039)
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(a) ROC Case 1

















(b) ROC Case 1

















(c) ROC Case 2

















(d) ROC Case 2

















(e) ROC Case 3

















(f) ROC Case 3
Figure B.1: Empirical ROC for Unpaired Design Simulation with independent and correlated
modality measurements
APPENDIX B. APPENDICES FOR CHAPTER 3 124
B.2 Details of Simulation for Breat Cancer Screening
Specifically, age X1 is simulated from a folded standard normal distribution which is the absolute
value of a random variable following standard normal distribution, and BRCA gene type X2 is
generated from Bernoulli(0.1). The indicator for disease outcome D is generated from from a logistic
model with logit(Pr(D = 1|X) = X1 +X2 − 0.8. For simplicity, we assume the screening outcome
of mammography and MRI to be binary indicators of whether abnormality is detected, which is
followed by a decision of whether biopsy should be referred. Modality A represents mammography
alone, where YA = 1 denotes the detection of abnormality under this modality. There are two
variables influencing YA are X3 and X4, where density of breast X3 is simulated from a folded
normal distribution, and tumor size (X4) is simulated by X4 = 0.3X1+0.7e1, with e1 simulated from
a folded standard normal distribution. The binary outcome representing detection of abnormality
is simulated from
YA ∼ Bernoulli(1, p)
where p is 0.01 + 0.98D − 0.4I(X4 < 0.1)D − 0.4I(X3 > 0.9)D) truncated by [0, 1]. Modality B
represents combined mammography and MRI, where YB = 1 represents either mammography or
MRI test detects abnormality, and
YB = (YA = 1) or (Bernoulli(0.1 + 0.88D) = 1).
The box plot of empirical AUCs of the two proposed methods are presented in Figure B.2.We
also observe a substantial increase in empirical AUC.



















Modality A Modality B wSVM1 wSVM2
Figure B.2: Empirical AUC for Breast Cancer based on n = 1000 and 100 replication
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Appendix C
Appendices for Chapter 4
C.1 Further Comparisons with Existing Literature
We compare MIRL with methods in [Johnson et al., 2008], [Garcia et al., 2010b], [Chen and Wang,
2013] (CW), and RRstep under Rubin’s rule (e.g., stepwise regression with p-value computed based
on Rubin’s rule standard error). We follow the same simulation settings reported in [Johnson et al.,
2008] and [Garcia et al., 2010b]. The results for the scenario in section 5.2 of [Johnson et al., 2008]
are presented in Table C.7. We can see that MIRL, RRstep and MILS show good performance
in variable selection and prediction in all four cases, and they outperform [Johnson et al., 2008].
MILS and RRstep perform similarly in this scenario and using stepwise selection does not lead to
better results than one-step backward selection (MILS). The simulation results from section 4.1 in
[Garcia et al., 2010b] are shown in Table C.8. MIRL outperforms all its competitors in terms of
variable selection. RRstep and MILS also have high MCC for scenario 1 and 3. CW gives good
MSPE for scenario 2 but the MCC is small. In these simulation settings, CW tends to select more
variables, where gains a larger true positives at the cost of selecting more noise variables.
Table C.9 presents simulation results comparing MIRL with RRstep and CW for p > n cases.
The simulation settings contain two pairs of n and p: n = 50, p = 100 and n = 100, p = 200. The
coefficients for x1, x2, . . . xp are β = (3, 1.5, 0, 0, 2, 0, . . . , 0), σ = 3, X1 and X2 missing at random
depending on X3 to X8 and outcome, and about 30% of subjects remain after listwise deletion. In
this case, MIRL outperforms the other two methods in terms of smaller prediction error, and has
similar performance in terms of MCC.
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C.2 Additional Simulation Results
Table C.1: Simulation Results for the Setting Described in Section 4.1 with p = 25 and Pairwise
Correlation 0.2
% left∗ L1 L2 MSPE TP TN MCC
LDLS 1.705(0.044) 0.371(0.016) 1.363(0.021) 5.97(0.119) 14.16(0.097) 0.603(0.012)
MILS 1.069(0.031) 0.154(0.008) 1.138(0.013) 7.38(0.095) 14.25(0.098) 0.725(0.012)
50% LD lasso cv 1.75(0.041) 0.289(0.014) 1.242(0.015) 8.4(0.147) 8.69(0.292) 0.437(0.017)
MIRLnoSS 1.489(0.03) 0.21(0.009) 1.18(0.014) 9.51(0.063) 4.37(0.157) 0.301(0.013)
MIRL 1.407(0.03) 0.262(0.011) 1.227(0.016) 6.02(0.122) 14.82(0.061) 0.673(0.01)
MCAR LDLS 3.086(0.073) 1.105(0.049) 1.969(0.044) 3.14(0.186) 14.3(0.104) 0.381(0.018)
MILS 1.119(0.032) 0.169(0.008) 1.153(0.012) 7.13(0.105) 14.32(0.091) 0.711(0.012)
25% LD lasso cv 2.576(0.067) 0.64(0.027) 1.518(0.026) 6.35(0.263) 9.76(0.367) 0.324(0.019)
MIRLnoSS 1.541(0.032) 0.223(0.009) 1.188(0.014) 9.45(0.067) 4.33(0.171) 0.288(0.014)
MIRL 1.473(0.035) 0.288(0.012) 1.243(0.015) 5.83(0.134) 14.82(0.052) 0.658(0.01)
LDLS 2.376(0.064) 0.701(0.032) 1.651(0.036) 4.4(0.16) 14.21(0.105) 0.474(0.016)
MILS 1.431(0.035) 0.241(0.01) 1.229(0.015) 7.39(0.121) 13.54(0.115) 0.663(0.015)
50% LD lasso cv 2.192(0.052) 0.434(0.019) 1.373(0.02) 7.63(0.171) 8.92(0.352) 0.372(0.021)
MAR MIRLnoSS 1.784(0.033) 0.302(0.011) 1.266(0.015) 9.41(0.065) 4.28(0.168) 0.283(0.014)
MIRL 1.654(0.036) 0.35(0.014) 1.31(0.016) 6.06(0.147) 14.62(0.09) 0.658(0.011)
LDLS 3.747(0.151) 1.716(0.168) 2.53(0.143) 2.37(0.166) 14.1(0.138) 0.294(0.021)
MILS 1.385(0.034) 0.234(0.01) 1.207(0.016) 7.33(0.129) 13.82(0.098) 0.681(0.015)
25% LD lasso cv 2.792(0.074) 0.773(0.034) 1.669(0.036) 5.76(0.279) 10.51(0.357) 0.315(0.022)
MIRLnoSS 1.805(0.033) 0.31(0.011) 1.263(0.016) 9.32(0.072) 4.27(0.167) 0.268(0.014)
MIRL 1.67(0.034) 0.358(0.013) 1.304(0.017) 5.84(0.143) 14.73(0.066) 0.65(0.01)
∗ Approx.% left after listwise deletion
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Table C.2: Simulation Results for the Setting Described in Section 4.1 with p = 25 and Pairwise
Correlation 0.6
% left∗ L1 L2 MSPE TP TN MCC
LDLS 2.418(0.06) 0.724(0.03) 1.514(0.037) 4.28(0.156) 14.31(0.088) 0.475(0.016)
MILS 1.536(0.037) 0.307(0.013) 1.203(0.017) 6.05(0.123) 14.38(0.089) 0.631(0.011)
50% LD lasso cv 2.27(0.052) 0.493(0.021) 1.224(0.015) 7.25(0.198) 9.72(0.313) 0.39(0.017)
MIRLnoSS 2.032(0.036) 0.39(0.014) 1.175(0.013) 9.34(0.076) 3.88(0.174) 0.243(0.016)
MIRL 1.912(0.04) 0.46(0.018) 1.219(0.014) 5.21(0.171) 14.46(0.123) 0.576(0.013)
MCAR LDLS 3.79(0.097) 1.694(0.09) 2.224(0.097) 1.87(0.147) 14.25(0.105) 0.248(0.017)
MILS 1.593(0.039) 0.337(0.014) 1.231(0.019) 5.8(0.123) 14.37(0.085) 0.609(0.012)
25% LD lasso cv 3.02(0.071) 0.928(0.033) 1.407(0.019) 4.47(0.296) 11.4(0.326) 0.262(0.022)
MIRLnoSS 2.104(0.038) 0.414(0.015) 1.186(0.012) 9.27(0.074) 3.58(0.161) 0.212(0.016)
MIRL 1.956(0.044) 0.483(0.02) 1.23(0.013) 4.97(0.181) 14.55(0.091) 0.569(0.014)
LDLS 3.207(0.065) 1.2(0.045) 1.942(0.076) 2.46(0.144) 14.32(0.089) 0.305(0.016)
MILS 2.056(0.047) 0.487(0.018) 1.308(0.02) 6.07(0.128) 13.28(0.121) 0.528(0.014)
50% LD lasso cv 2.741(0.064) 0.752(0.029) 1.365(0.017) 5.51(0.276) 10.77(0.36) 0.319(0.019)
MAR MIRLnoSS 2.227(0.037) 0.454(0.015) 1.222(0.013) 9.21(0.087) 3.95(0.19) 0.231(0.017)
MIRL 2.073(0.039) 0.517(0.018) 1.264(0.015) 5.38(0.171) 13.97(0.118) 0.537(0.014)
LDLS 4.125(0.176) 2.233(0.303) 2.735(0.402) 1.14(0.121) 14.23(0.114) 0.142(0.024)
MILS 2.003(0.044) 0.476(0.017) 1.328(0.024) 5.96(0.133) 13.57(0.112) 0.545(0.013)
25% LD lasso cv 3.176(0.113) 1.057(0.098) 1.539(0.075) 4.03(0.283) 11.44(0.337) 0.227(0.02)
MIRLnoSS 2.222(0.038) 0.453(0.015) 1.229(0.014) 9.18(0.086) 3.84(0.163) 0.222(0.016)
MIRL 2.06(0.04) 0.513(0.018) 1.272(0.016) 5.47(0.177) 14.02(0.114) 0.549(0.015)
∗ Approx.% left after listwise deletion
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Table C.3: Simulation Results for the Setting Described in Section 4.1 with p = 50 and Pairwise
Correlation 0.2
% left∗ L1 L2 MSPE TP TN MCC
LDLS 2.742(0.087) 0.796(0.036) 1.721(0.039) 4.87(0.166) 37.83(0.206) 0.512(0.016)
MILS 1.403(0.036) 0.234(0.01) 1.205(0.015) 7.43(0.102) 38.22(0.135) 0.726(0.011)
50% LD lasso cv 2.408(0.07) 0.405(0.015) 1.332(0.021) 8.17(0.13) 27.39(0.626) 0.426(0.012)
MIRLnoSS 2.333(0.034) 0.293(0.009) 1.239(0.016) 9.6(0.053) 9.5(0.282) 0.197(0.008)
MIRL 1.424(0.031) 0.253(0.01) 1.208(0.016) 6.83(0.105) 39.29(0.13) 0.75(0.01)
MCAR LDLS 5.946(0.624) 6.475(1.443) 6.637(1.181) 0.875(0.215) 38.286(0.507) 0.175(0.042)
MILS 1.428(0.037) 0.245(0.011) 1.218(0.017) 7.16(0.104) 38.36(0.133) 0.714(0.011)
25% LD lasso cv 3.539(0.186) 0.985(0.082) 1.799(0.066) 5.38(0.261) 30.56(0.845) 0.307(0.017)
MIRLnoSS 2.366(0.034) 0.299(0.009) 1.238(0.015) 9.59(0.057) 9.01(0.263) 0.188(0.008)
MIRL 1.458(0.03) 0.266(0.01) 1.223(0.016) 6.59(0.114) 39.34(0.109) 0.734(0.01)
LDLS 4.179(0.238) 2.021(0.32) 2.837(0.258) 2.152(0.171) 38.152(0.239) 0.28(0.019)
MILS 2.203(0.07) 0.446(0.019) 1.424(0.021) 7.14(0.119) 35.49(0.267) 0.581(0.015)
50% LD lasso cv 2.879(0.091) 0.632(0.031) 1.536(0.028) 6.85(0.213) 29.41(0.677) 0.381(0.015)
MAR MIRLnoSS 2.799(0.041) 0.411(0.012) 1.37(0.016) 9.7(0.05) 8.16(0.269) 0.184(0.008)
MIRL 1.891(0.043) 0.382(0.013) 1.35(0.017) 6.67(0.144) 37.24(0.351) 0.642(0.013)
LDLS 5.303(1.752) 9.472(8.068) 10.149(7.689) 0(0) 40(0) NaN(NA)
MILS 2.087(0.057) 0.428(0.017) 1.366(0.019) 6.89(0.117) 36.28(0.206) 0.591(0.013)
25% LD lasso cv 3.63(0.113) 1.085(0.044) 1.916(0.041) 4.05(0.263) 32.29(0.737) 0.259(0.016)
MIRLnoSS 2.781(0.04) 0.409(0.012) 1.34(0.016) 9.71(0.054) 7.85(0.333) 0.178(0.009)
MIRL 1.893(0.041) 0.384(0.013) 1.321(0.016) 6.59(0.133) 37.28(0.344) 0.635(0.013)
∗ Approx.% left after listwise deletion
Table C.4: Simulation Results for the Setting Described in Section 4.1 with p = 50 and Pairwise
Correlation 0.6
% left∗ L1 L2 MSPE TP TN MCC
LDLS 3.746(0.119) 1.44(0.067) 2.072(0.084) 3.39(0.16) 37.71(0.211) 0.365(0.019)
MILS 2.043(0.055) 0.478(0.019) 1.372(0.031) 5.87(0.104) 37.99(0.162) 0.598(0.012)
50% LD lasso cv 2.843(0.069) 0.66(0.025) 1.269(0.016) 6.05(0.236) 31.07(0.616) 0.376(0.015)
MIRLnoSS 3.046(0.043) 0.504(0.015) 1.213(0.014) 9.45(0.066) 8.1(0.27) 0.156(0.008)
MIRL 2.13(0.044) 0.472(0.016) 1.226(0.015) 6.07(0.146) 37.14(0.316) 0.588(0.011)
MCAR LDLS 6.986(0.962) 9.495(2.528) 7.595(1.885) 0.607(0.178) 38.071(0.571) 0.059(0.035)
MILS 2.064(0.056) 0.496(0.02) 1.422(0.035) 5.62(0.099) 38.12(0.153) 0.586(0.011)
25% LD lasso cv 3.782(0.183) 1.245(0.103) 1.521(0.044) 3.65(0.274) 32.97(0.742) 0.249(0.017)
MIRLnoSS 3.099(0.045) 0.517(0.015) 1.218(0.014) 9.54(0.063) 8.01(0.281) 0.163(0.009)
MIRL 2.158(0.045) 0.48(0.015) 1.243(0.014) 6.09(0.141) 37.05(0.384) 0.592(0.013)
LDLS 5.375(0.316) 3.631(0.422) 3.238(0.278) 1.273(0.129) 38.071(0.277) 0.169(0.022)
MILS 3.287(0.094) 0.921(0.035) 1.667(0.042) 5.53(0.142) 34.92(0.242) 0.425(0.016)
50% LD lasso cv 3.298(0.089) 0.928(0.03) 1.409(0.017) 4.21(0.267) 33.23(0.625) 0.302(0.016)
MAR MIRLnoSS 3.609(0.05) 0.677(0.018) 1.307(0.014) 9.42(0.074) 7.36(0.272) 0.139(0.009)
MIRL 2.778(0.067) 0.651(0.021) 1.324(0.016) 6.32(0.169) 33.3(0.564) 0.462(0.015)
LDLS NaN(NA) NaN(NA) NaN(NA) NaN(NA) NaN(NA) NaN(NA)
MILS 3.248(0.088) 0.914(0.034) 1.704(0.046) 5.36(0.138) 35.24(0.217) 0.421(0.015)
25% LD lasso cv 3.645(0.119) 1.22(0.052) 1.559(0.026) 2.26(0.253) 35.43(0.619) 0.187(0.021)
MIRLnoSS 3.594(0.052) 0.665(0.018) 1.296(0.015) 9.5(0.067) 6.7(0.313) 0.131(0.01)
MIRL 2.757(0.064) 0.645(0.021) 1.326(0.016) 6.22(0.174) 33.36(0.564) 0.455(0.015)
∗ Approx.% left after listwise deletion
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Table C.5: Simulation Results for the Setting Described in Section 4.1 with p = 100 and Pairwise
Correlation 0.2
% left∗ L1 L2 MSPE TP TN MCC
LDLS 6.662(0.946) 5.162(1.031) 6.018(1.106) 0.739(0.212) 86.283(1.332) 0.104(0.033)
MILS 2.466(0.078) 0.544(0.021) 1.526(0.029) 6.43(0.111) 85.39(0.307) 0.583(0.012)
50% LD lasso cv 2.754(0.077) 0.529(0.02) 1.428(0.021) 6.59(0.176) 75.89(0.864) 0.397(0.011)
MIRLnoSS 3.682(0.049) 0.418(0.011) 1.346(0.016) 9.49(0.063) 22.16(0.466) 0.141(0.005)
MIRL 1.745(0.041) 0.311(0.011) 1.273(0.015) 7.1(0.095) 87(0.302) 0.689(0.009)
MCAR LDLS NaN(NA) NaN(NA) NaN(NA) NaN(NA) NaN(NA) NaN(NA)
MILS 2.374(0.075) 0.533(0.021) 1.517(0.028) 6.18(0.111) 86.05(0.282) 0.586(0.012)
25% LD lasso cv 3.551(0.105) 0.946(0.028) 1.794(0.032) 4.01(0.24) 79.11(1.04) 0.294(0.013)
MIRLnoSS 3.712(0.049) 0.429(0.012) 1.376(0.016) 9.49(0.064) 21.4(0.476) 0.136(0.005)
MIRL 1.761(0.044) 0.325(0.012) 1.299(0.016) 6.92(0.099) 87.23(0.373) 0.688(0.009)
LDLS NaN(NA) NaN(NA) NaN(NA) NaN(NA) NaN(NA) NaN(NA)
MILS 6.023(0.204) 1.737(0.072) 2.535(0.071) 5.87(0.134) 75.02(0.645) 0.326(0.014)
50% LD lasso cv 3.239(0.112) 0.715(0.028) 1.582(0.03) 5.78(0.213) 76.11(1.118) 0.355(0.012)
MAR MIRLnoSS 5.026(0.066) 0.759(0.019) 1.602(0.02) 9.53(0.07) 16.78(0.443) 0.11(0.007)
MIRL 3.134(0.089) 0.683(0.021) 1.552(0.021) 6.32(0.17) 79.25(0.955) 0.456(0.015)
LDLS NaN(NA) NaN(NA) NaN(NA) NaN(NA) NaN(NA) NaN(NA)
MILS 5.362(0.178) 1.596(0.065) 2.465(0.06) 5.35(0.14) 78.16(0.542) 0.334(0.014)
25% LD lasso cv 3.823(0.105) 1.195(0.032) 2.02(0.035) 2.6(0.244) 82.17(0.855) 0.206(0.017)
MIRLnoSS 4.958(0.061) 0.737(0.018) 1.64(0.022) 9.48(0.063) 16.41(0.407) 0.104(0.005)
MIRL 3.015(0.082) 0.664(0.02) 1.579(0.023) 6.26(0.163) 80.18(0.848) 0.467(0.014)
∗ Approx.% left after listwise deletion
Table C.6: Simulation Results for the Setting Described in Section 4.1 with p = 100 and Pairwise
Correlation 0.6
% left∗ L1 L2 MSPE TP TN MCC
LDLS 8.317(1.357) 8.944(1.951) 7.478(1.716) 0.63(0.187) 86.261(1.273) 0.079(0.032)
MILS 3.576(0.11) 1.136(0.044) 1.959(0.077) 4.64(0.128) 85.5(0.292) 0.444(0.013)
50% LD lasso cv 3.451(0.117) 0.836(0.028) 1.349(0.017) 4.74(0.256) 77.33(1.201) 0.323(0.014)
MIRLnoSS 4.814(0.063) 0.707(0.019) 1.299(0.015) 9.34(0.082) 18.38(0.43) 0.106(0.007)
MIRL 2.633(0.077) 0.571(0.019) 1.303(0.018) 6.02(0.146) 82.37(0.912) 0.506(0.013)
MCAR LDLS NaN(NA) NaN(NA) NaN(NA) NaN(NA) NaN(NA) NaN(NA)
MILS 3.404(0.101) 1.095(0.043) 1.927(0.059) 4.34(0.124) 86.21(0.258) 0.444(0.013)
25% LD lasso cv 3.829(0.148) 1.193(0.048) 1.509(0.025) 2.29(0.241) 82.56(1.03) 0.209(0.018)
MIRLnoSS 4.827(0.063) 0.715(0.02) 1.316(0.016) 9.31(0.072) 17.86(0.439) 0.099(0.007)
MIRL 2.639(0.071) 0.587(0.02) 1.338(0.018) 5.97(0.138) 82.93(0.796) 0.505(0.013)
LDLS NaN(NA) NaN(NA) NaN(NA) NaN(NA) NaN(NA) NaN(NA)
MILS 9.291(0.248) 3.574(0.122) 3.08(0.092) 4.4(0.162) 72.09(0.597) 0.18(0.013)
50% LD lasso cv 3.565(0.116) 0.991(0.032) 1.455(0.02) 3.39(0.266) 80.62(1.029) 0.259(0.016)
MAR MIRLnoSS 6.717(0.101) 1.243(0.033) 1.562(0.024) 9.5(0.064) 12.32(0.366) 0.076(0.007)
MIRL 4.969(0.119) 1.171(0.034) 1.562(0.025) 6.21(0.196) 66.46(1.295) 0.263(0.013)
LDLS NaN(NA) NaN(NA) NaN(NA) NaN(NA) NaN(NA) NaN(NA)
MILS 8.231(0.235) 3.273(0.119) 3.177(0.161) 3.84(0.152) 75.92(0.527) 0.183(0.013)
25% LD lasso cv 4.046(0.165) 1.373(0.06) 1.625(0.033) 1.63(0.195) 83.52(0.927) 0.169(0.019)
MIRLnoSS 6.625(0.104) 1.22(0.034) 1.518(0.022) 9.51(0.063) 12.58(0.373) 0.079(0.007)
MIRL 4.957(0.137) 1.16(0.036) 1.531(0.025) 6.11(0.21) 64.59(1.637) 0.245(0.014)
∗ Approx.% left after listwise deletion
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Table C.7: Comparison for the Scenario in Section 5.2
L1 L2 MPSE TP TN MCC
MILS 0.52 0.07 1.07 5.65 3.81 0.90
LDlasso 0.97 0.16 1.15 5.98 1.73 0.62
Setting 1 MIRL 0.65 0.11 1.09 5.30 3.84 0.85
σ = 1 CW 0.59 0.07 1.06 5.99 2.75 0.75
RRstep 0.56 0.08 1.06 5.63 3.85 0.90
JohnLas 5.91 2.42 0.67
JohnALas 5.77 3.55 0.86
MILS 1.08 0.30 1.25 4.92 3.81 0.76
LDlasso 2.37 1.02 2.08 5.67 2.01 0.57
Setting 1 MIRL 1.28 0.40 1.31 4.75 3.87 0.76
σ = 2 CW 1.10 0.23 1.17 5.70 2.89 0.71
RRstep 1.13 0.28 1.19 5.07 3.79 0.78
JohnLas 4.88 3.70 0.72
JohnALas 5.60 2.54 0.61
MILS 0.29 0.04 1.03 3.00 6.67 0.94
LDlasso 0.87 0.16 1.14 3.00 3.48 0.52
Setting 2 MIRL 0.27 0.03 1.02 3.00 6.60 0.95
σ = 1 CW 0.48 0.06 1.04 3.00 4.95 0.66
RRstep 0.31 0.04 1.03 3.00 6.63 0.93
JohnLas 3.00 4.11 0.55
JohnALas 3.00 6.25 0.85
MILS 0.56 0.15 1.15 3.00 6.64 0.93
LDlasso 2.14 0.99 2.01 3.00 3.79 0.55
Setting 2 MIRL 0.50 0.10 1.12 3.00 6.69 0.95
σ = 2 CW 0.85 0.19 1.18 3.00 5.02 0.67
RRstep 0.54 0.12 1.13 3.00 6.72 0.95
JohnLas 2.98 4.56 0.59
JohnALas 2.98 6.08 0.81
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Table C.8: Comparison for Scenario in Section 4.1
L1 L2 MPSE TP TN MCC
MILS 1.04 0.58 1.67 2.98 4.87 0.97
LDlasso 1.57 0.59 1.56 3.00 2.24 0.54
n = 40 MIRL 1.21 0.65 1.77 2.98 4.83 0.98
σ = 1 CW 1.72 0.77 1.81 3.00 3.09 0.64
RRstep 1.31 0.72 1.75 2.96 4.80 0.95
GarciaAlasso 3.00 4.64 0.91
GarciaSCAD 3.00 4.64 0.91
MILS 3.75 6.26 6.67 2.07 4.76 0.73
LDlasso 5.20 6.32 7.31 2.74 2.65 0.50
n = 40 MIRL 3.82 5.55 6.31 2.24 4.71 0.80
σ = 3 CW 3.77 3.94 4.40 2.93 3.49 0.68
RRstep 4.26 6.60 5.53 2.24 4.65 0.71
GarciaAlasso 2.72 4.31 0.75
GarciaSCAD 2.67 4.53 0.79
MILS 0.87 0.38 1.33 2.99 4.76 0.95
LDlasso 1.30 0.39 1.34 3.00 2.48 0.62
n = 60 MIRL 0.86 0.31 1.29 2.99 4.98 0.99
σ = 1 CW 1.31 0.45 1.40 3.00 3.24 0.65
RRstep 1.00 0.40 1.33 2.99 4.76 0.94
GarciaAlasso 3.00 4.83 0.96
GarciaSCAD 3.00 4.86 0.96
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Table C.9: Comparison of MIRL with CW and RRstep for High-Dimensional Scenarios with p > n
Settings L1 L2 MPSE TP TN MCC
n = 50 MIRL 9.55 16.51 19.50 1.12 92.93 0.27
p = 100 RRstep 14.01 25.78 26.23 1.23 91.22 0.27
CW 35.94 42.04 42.15 2.65 43.32 0.13
n = 100 MIRL 10.03 13.59 15.67 1.74 187.48 0.31
p = 200 RRstep 18.36 25.04 24.71 1.62 182.22 0.25
CW 24.96 28.15 27.95 2.26 153.72 0.35
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C.3 Subgroup Analysis
Table C.10: MIRL Selected Sequence of Important Variables Compared with MILS Selection for
Low-Income Boys
Variables MIRL MILS
raw est. Prob raw est. p-value
Parental weight status 0.0689 0.9115 0.2347 0.5188
Distance to nearest recreation center(m) -0.1039 0.7950 -0.2779 0.3471
Competitive food with policies -0.1286 0.7590 -0.3597 0.5438
Park/recreation space (% of area) -0.0035 0.7160 -0.0437 0.8842
Poor quality of fruits/vegetables 0.0386 0.7060 0.0038 0.9904
Friends’ attitudes of eating healthy foods 0.0359 0.7030 0.4056 0.1383
During the night -0.1511 0.6985 -0.2100 0.6564
TV during dinner -0.1696 0.6715 -0.4001 0.0751
Fast-food frequency male friends -0.0719 0.6630 -0.3674 0.3973
Number of male friends in sample 0.0344 0.6255 -0.0505 0.8755
Parental fast food intake 0.0382 0.5975 -0.0226 0.9333
